WO2022160138A1 - 苯并嗪-4-酮类化合物、其制备方法及医药用途 - Google Patents
苯并嗪-4-酮类化合物、其制备方法及医药用途 Download PDFInfo
- Publication number
- WO2022160138A1 WO2022160138A1 PCT/CN2021/074002 CN2021074002W WO2022160138A1 WO 2022160138 A1 WO2022160138 A1 WO 2022160138A1 CN 2021074002 W CN2021074002 W CN 2021074002W WO 2022160138 A1 WO2022160138 A1 WO 2022160138A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- carbons
- unsubstituted
- acid
- substituted
- branched
- Prior art date
Links
- -1 Benzoxazine-4-one compound Chemical class 0.000 title claims abstract description 27
- 238000002360 preparation method Methods 0.000 title claims abstract description 15
- 229920002527 Glycogen Polymers 0.000 claims abstract description 15
- 229940096919 glycogen Drugs 0.000 claims abstract description 15
- 239000003814 drug Substances 0.000 claims abstract description 10
- ROJNYKZWTOHRNU-UHFFFAOYSA-N 2-chloro-4,5-difluoro-n-[[2-methoxy-5-(methylcarbamoylamino)phenyl]carbamoyl]benzamide Chemical compound CNC(=O)NC1=CC=C(OC)C(NC(=O)NC(=O)C=2C(=CC(F)=C(F)C=2)Cl)=C1 ROJNYKZWTOHRNU-UHFFFAOYSA-N 0.000 claims abstract description 4
- 230000006806 disease prevention Effects 0.000 claims abstract 2
- ZMXDDKWLCZADIW-UHFFFAOYSA-N N,N-Dimethylformamide Chemical compound CN(C)C=O ZMXDDKWLCZADIW-UHFFFAOYSA-N 0.000 claims description 96
- LFQSCWFLJHTTHZ-UHFFFAOYSA-N Ethanol Chemical compound CCO LFQSCWFLJHTTHZ-UHFFFAOYSA-N 0.000 claims description 74
- YXFVVABEGXRONW-UHFFFAOYSA-N Toluene Chemical compound CC1=CC=CC=C1 YXFVVABEGXRONW-UHFFFAOYSA-N 0.000 claims description 60
- 150000001875 compounds Chemical class 0.000 claims description 53
- ZMANZCXQSJIPKH-UHFFFAOYSA-N Triethylamine Chemical compound CCN(CC)CC ZMANZCXQSJIPKH-UHFFFAOYSA-N 0.000 claims description 36
- 239000000203 mixture Substances 0.000 claims description 34
- OKKJLVBELUTLKV-UHFFFAOYSA-N Methanol Chemical group OC OKKJLVBELUTLKV-UHFFFAOYSA-N 0.000 claims description 30
- IAZDPXIOMUYVGZ-UHFFFAOYSA-N Dimethylsulphoxide Chemical compound CS(C)=O IAZDPXIOMUYVGZ-UHFFFAOYSA-N 0.000 claims description 29
- 125000000217 alkyl group Chemical group 0.000 claims description 26
- YMWUJEATGCHHMB-UHFFFAOYSA-N Dichloromethane Chemical compound ClCCl YMWUJEATGCHHMB-UHFFFAOYSA-N 0.000 claims description 24
- 239000003960 organic solvent Substances 0.000 claims description 20
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims description 18
- WYURNTSHIVDZCO-UHFFFAOYSA-N Tetrahydrofuran Chemical compound C1CCOC1 WYURNTSHIVDZCO-UHFFFAOYSA-N 0.000 claims description 16
- WEVYAHXRMPXWCK-UHFFFAOYSA-N Acetonitrile Chemical compound CC#N WEVYAHXRMPXWCK-UHFFFAOYSA-N 0.000 claims description 15
- 150000003839 salts Chemical class 0.000 claims description 13
- HEDRZPFGACZZDS-UHFFFAOYSA-N Chloroform Chemical compound ClC(Cl)Cl HEDRZPFGACZZDS-UHFFFAOYSA-N 0.000 claims description 12
- 239000007821 HATU Substances 0.000 claims description 12
- 101100272976 Panax ginseng CYP716A53v2 gene Proteins 0.000 claims description 12
- DKGAVHZHDRPRBM-UHFFFAOYSA-N Tert-Butanol Chemical compound CC(C)(C)O DKGAVHZHDRPRBM-UHFFFAOYSA-N 0.000 claims description 12
- VLKZOEOYAKHREP-UHFFFAOYSA-N n-Hexane Chemical compound CCCCCC VLKZOEOYAKHREP-UHFFFAOYSA-N 0.000 claims description 12
- ZDYVRSLAEXCVBX-UHFFFAOYSA-N pyridinium p-toluenesulfonate Chemical compound C1=CC=[NH+]C=C1.CC1=CC=C(S([O-])(=O)=O)C=C1 ZDYVRSLAEXCVBX-UHFFFAOYSA-N 0.000 claims description 12
- VEXZGXHMUGYJMC-UHFFFAOYSA-N Hydrochloric acid Chemical compound Cl VEXZGXHMUGYJMC-UHFFFAOYSA-N 0.000 claims description 11
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims description 11
- 125000000304 alkynyl group Chemical group 0.000 claims description 10
- 229910052757 nitrogen Inorganic materials 0.000 claims description 10
- 125000002023 trifluoromethyl group Chemical group FC(F)(F)* 0.000 claims description 10
- JUJWROOIHBZHMG-UHFFFAOYSA-N Pyridine Chemical compound C1=CC=NC=C1 JUJWROOIHBZHMG-UHFFFAOYSA-N 0.000 claims description 9
- 229910052794 bromium Inorganic materials 0.000 claims description 9
- 229910052801 chlorine Inorganic materials 0.000 claims description 9
- 239000000460 chlorine Substances 0.000 claims description 9
- 229910052731 fluorine Inorganic materials 0.000 claims description 9
- 239000008194 pharmaceutical composition Substances 0.000 claims description 9
- 238000010992 reflux Methods 0.000 claims description 9
- WSLDOOZREJYCGB-UHFFFAOYSA-N 1,2-Dichloroethane Chemical compound ClCCCl WSLDOOZREJYCGB-UHFFFAOYSA-N 0.000 claims description 8
- KFZMGEQAYNKOFK-UHFFFAOYSA-N Isopropanol Chemical compound CC(C)O KFZMGEQAYNKOFK-UHFFFAOYSA-N 0.000 claims description 8
- LRHPLDYGYMQRHN-UHFFFAOYSA-N N-Butanol Chemical compound CCCCO LRHPLDYGYMQRHN-UHFFFAOYSA-N 0.000 claims description 8
- 230000002159 abnormal effect Effects 0.000 claims description 8
- 125000003545 alkoxy group Chemical group 0.000 claims description 8
- 239000003054 catalyst Substances 0.000 claims description 8
- 229910052739 hydrogen Inorganic materials 0.000 claims description 8
- 230000004060 metabolic process Effects 0.000 claims description 8
- YLQBMQCUIZJEEH-UHFFFAOYSA-N tetrahydrofuran Natural products C=1C=COC=1 YLQBMQCUIZJEEH-UHFFFAOYSA-N 0.000 claims description 8
- QAOWNCQODCNURD-UHFFFAOYSA-N Sulfuric acid Chemical compound OS(O)(=O)=O QAOWNCQODCNURD-UHFFFAOYSA-N 0.000 claims description 7
- 239000003153 chemical reaction reagent Substances 0.000 claims description 7
- 201000010099 disease Diseases 0.000 claims description 7
- 229910052736 halogen Inorganic materials 0.000 claims description 7
- 150000002367 halogens Chemical class 0.000 claims description 7
- 229910052740 iodine Inorganic materials 0.000 claims description 7
- 208000031225 myocardial ischemia Diseases 0.000 claims description 7
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims description 7
- 208000001072 type 2 diabetes mellitus Diseases 0.000 claims description 7
- WVDDGKGOMKODPV-UHFFFAOYSA-N Benzyl alcohol Chemical compound OCC1=CC=CC=C1 WVDDGKGOMKODPV-UHFFFAOYSA-N 0.000 claims description 6
- XDTMQSROBMDMFD-UHFFFAOYSA-N Cyclohexane Chemical compound C1CCCCC1 XDTMQSROBMDMFD-UHFFFAOYSA-N 0.000 claims description 6
- AFVFQIVMOAPDHO-UHFFFAOYSA-N Methanesulfonic acid Chemical compound CS(O)(=O)=O AFVFQIVMOAPDHO-UHFFFAOYSA-N 0.000 claims description 6
- BZLVMXJERCGZMT-UHFFFAOYSA-N Methyl tert-butyl ether Chemical compound COC(C)(C)C BZLVMXJERCGZMT-UHFFFAOYSA-N 0.000 claims description 6
- QOSSAOTZNIDXMA-UHFFFAOYSA-N N,N′-Dicyclohexylcarbodiimide Substances C1CCCCC1N=C=NC1CCCCC1 QOSSAOTZNIDXMA-UHFFFAOYSA-N 0.000 claims description 6
- 208000006011 Stroke Diseases 0.000 claims description 6
- 125000003342 alkenyl group Chemical group 0.000 claims description 6
- 125000003178 carboxy group Chemical group [H]OC(*)=O 0.000 claims description 6
- 208000026106 cerebrovascular disease Diseases 0.000 claims description 6
- 238000009833 condensation Methods 0.000 claims description 6
- 230000005494 condensation Effects 0.000 claims description 6
- 125000004093 cyano group Chemical group *C#N 0.000 claims description 6
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims description 6
- 239000001257 hydrogen Substances 0.000 claims description 6
- 239000011261 inert gas Substances 0.000 claims description 6
- 125000000959 isobutyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])* 0.000 claims description 6
- 125000001449 isopropyl group Chemical group [H]C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 6
- BDAGIHXWWSANSR-UHFFFAOYSA-N methanoic acid Natural products OC=O BDAGIHXWWSANSR-UHFFFAOYSA-N 0.000 claims description 6
- 238000000034 method Methods 0.000 claims description 6
- 125000000956 methoxy group Chemical group [H]C([H])([H])O* 0.000 claims description 6
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims description 6
- 125000004108 n-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 6
- VHUUQVKOLVNVRT-UHFFFAOYSA-N Ammonium hydroxide Chemical compound [NH4+].[OH-] VHUUQVKOLVNVRT-UHFFFAOYSA-N 0.000 claims description 5
- 235000011114 ammonium hydroxide Nutrition 0.000 claims description 5
- 125000003118 aryl group Chemical group 0.000 claims description 5
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims description 5
- 206010012601 diabetes mellitus Diseases 0.000 claims description 5
- 125000001072 heteroaryl group Chemical class 0.000 claims description 5
- 150000007522 mineralic acids Chemical class 0.000 claims description 5
- 125000000962 organic group Chemical group 0.000 claims description 5
- 229910052760 oxygen Inorganic materials 0.000 claims description 5
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 5
- RYHBNJHYFVUHQT-UHFFFAOYSA-N 1,4-Dioxane Chemical compound C1COCCO1 RYHBNJHYFVUHQT-UHFFFAOYSA-N 0.000 claims description 4
- LMDZBCPBFSXMTL-UHFFFAOYSA-N 1-Ethyl-3-(3-dimethylaminopropyl)carbodiimide Substances CCN=C=NCCCN(C)C LMDZBCPBFSXMTL-UHFFFAOYSA-N 0.000 claims description 4
- FPQQSJJWHUJYPU-UHFFFAOYSA-N 3-(dimethylamino)propyliminomethylidene-ethylazanium;chloride Chemical compound Cl.CCN=C=NCCCN(C)C FPQQSJJWHUJYPU-UHFFFAOYSA-N 0.000 claims description 4
- NLXLAEXVIDQMFP-UHFFFAOYSA-N Ammonia chloride Chemical compound [NH4+].[Cl-] NLXLAEXVIDQMFP-UHFFFAOYSA-N 0.000 claims description 4
- 125000001313 C5-C10 heteroaryl group Chemical class 0.000 claims description 4
- 208000024172 Cardiovascular disease Diseases 0.000 claims description 4
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims description 4
- JGFZNNIVVJXRND-UHFFFAOYSA-N N,N-Diisopropylethylamine (DIPEA) Chemical group CCN(C(C)C)C(C)C JGFZNNIVVJXRND-UHFFFAOYSA-N 0.000 claims description 4
- CTQNGGLPUBDAKN-UHFFFAOYSA-N O-Xylene Chemical compound CC1=CC=CC=C1C CTQNGGLPUBDAKN-UHFFFAOYSA-N 0.000 claims description 4
- CDBYLPFSWZWCQE-UHFFFAOYSA-L Sodium Carbonate Chemical group [Na+].[Na+].[O-]C([O-])=O CDBYLPFSWZWCQE-UHFFFAOYSA-L 0.000 claims description 4
- 150000001336 alkenes Chemical class 0.000 claims description 4
- HSFWRNGVRCDJHI-UHFFFAOYSA-N alpha-acetylene Natural products C#C HSFWRNGVRCDJHI-UHFFFAOYSA-N 0.000 claims description 4
- 150000001412 amines Chemical class 0.000 claims description 4
- 125000004432 carbon atom Chemical group C* 0.000 claims description 4
- 206010008118 cerebral infarction Diseases 0.000 claims description 4
- HGCIXCUEYOPUTN-UHFFFAOYSA-N cyclohexene Chemical compound C1CCC=CC1 HGCIXCUEYOPUTN-UHFFFAOYSA-N 0.000 claims description 4
- 125000001028 difluoromethyl group Chemical group [H]C(F)(F)* 0.000 claims description 4
- 230000002526 effect on cardiovascular system Effects 0.000 claims description 4
- 125000002534 ethynyl group Chemical group [H]C#C* 0.000 claims description 4
- QEWYKACRFQMRMB-UHFFFAOYSA-N fluoroacetic acid Chemical compound OC(=O)CF QEWYKACRFQMRMB-UHFFFAOYSA-N 0.000 claims description 4
- 125000004216 fluoromethyl group Chemical group [H]C([H])(F)* 0.000 claims description 4
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims description 4
- 150000007529 inorganic bases Chemical class 0.000 claims description 4
- 230000000302 ischemic effect Effects 0.000 claims description 4
- ZXEKIIBDNHEJCQ-UHFFFAOYSA-N isobutanol Chemical compound CC(C)CO ZXEKIIBDNHEJCQ-UHFFFAOYSA-N 0.000 claims description 4
- 229910052751 metal Inorganic materials 0.000 claims description 4
- 239000002184 metal Substances 0.000 claims description 4
- UHOVQNZJYSORNB-UHFFFAOYSA-N monobenzene Natural products C1=CC=CC=C1 UHOVQNZJYSORNB-UHFFFAOYSA-N 0.000 claims description 4
- 150000007524 organic acids Chemical class 0.000 claims description 4
- BWHMMNNQKKPAPP-UHFFFAOYSA-L potassium carbonate Chemical compound [K+].[K+].[O-]C([O-])=O BWHMMNNQKKPAPP-UHFFFAOYSA-L 0.000 claims description 4
- 125000000391 vinyl group Chemical group [H]C([*])=C([H])[H] 0.000 claims description 4
- 229920002554 vinyl polymer Polymers 0.000 claims description 4
- 239000008096 xylene Substances 0.000 claims description 4
- OSWFIVFLDKOXQC-UHFFFAOYSA-N 4-(3-methoxyphenyl)aniline Chemical compound COC1=CC=CC(C=2C=CC(N)=CC=2)=C1 OSWFIVFLDKOXQC-UHFFFAOYSA-N 0.000 claims description 3
- 206010022489 Insulin Resistance Diseases 0.000 claims description 3
- 208000035475 disorder Diseases 0.000 claims description 3
- 235000019253 formic acid Nutrition 0.000 claims description 3
- 201000001421 hyperglycemia Diseases 0.000 claims description 3
- 229940098779 methanesulfonic acid Drugs 0.000 claims description 3
- 125000004123 n-propyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 3
- 125000001624 naphthyl group Chemical group 0.000 claims description 3
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims description 3
- UMJSCPRVCHMLSP-UHFFFAOYSA-N pyridine Natural products COC1=CC=CN=C1 UMJSCPRVCHMLSP-UHFFFAOYSA-N 0.000 claims description 3
- 229910052717 sulfur Inorganic materials 0.000 claims description 3
- TXUICONDJPYNPY-UHFFFAOYSA-N (1,10,13-trimethyl-3-oxo-4,5,6,7,8,9,11,12,14,15,16,17-dodecahydrocyclopenta[a]phenanthren-17-yl) heptanoate Chemical compound C1CC2CC(=O)C=C(C)C2(C)C2C1C1CCC(OC(=O)CCCCCC)C1(C)CC2 TXUICONDJPYNPY-UHFFFAOYSA-N 0.000 claims description 2
- NWZSZGALRFJKBT-KNIFDHDWSA-N (2s)-2,6-diaminohexanoic acid;(2s)-2-hydroxybutanedioic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O.NCCCC[C@H](N)C(O)=O NWZSZGALRFJKBT-KNIFDHDWSA-N 0.000 claims description 2
- KBHQUFPZXCNYKN-UHFFFAOYSA-N 1h-pyrrolo[3,2-b]pyridine-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=N1 KBHQUFPZXCNYKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010002383 Angina Pectoris Diseases 0.000 claims description 2
- 201000001320 Atherosclerosis Diseases 0.000 claims description 2
- 201000006474 Brain Ischemia Diseases 0.000 claims description 2
- 125000005915 C6-C14 aryl group Chemical group 0.000 claims description 2
- OKTJSMMVPCPJKN-UHFFFAOYSA-N Carbon Chemical compound [C] OKTJSMMVPCPJKN-UHFFFAOYSA-N 0.000 claims description 2
- 206010008120 Cerebral ischaemia Diseases 0.000 claims description 2
- GSNUFIFRDBKVIE-UHFFFAOYSA-N DMF Natural products CC1=CC=C(C)O1 GSNUFIFRDBKVIE-UHFFFAOYSA-N 0.000 claims description 2
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims description 2
- 208000032131 Diabetic Neuropathies Diseases 0.000 claims description 2
- 208000008960 Diabetic foot Diseases 0.000 claims description 2
- 206010060378 Hyperinsulinaemia Diseases 0.000 claims description 2
- 208000031226 Hyperlipidaemia Diseases 0.000 claims description 2
- 206010020772 Hypertension Diseases 0.000 claims description 2
- HCUARRIEZVDMPT-UHFFFAOYSA-N Indole-2-carboxylic acid Chemical class C1=CC=C2NC(C(=O)O)=CC2=C1 HCUARRIEZVDMPT-UHFFFAOYSA-N 0.000 claims description 2
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 claims description 2
- 208000001145 Metabolic Syndrome Diseases 0.000 claims description 2
- 206010028980 Neoplasm Diseases 0.000 claims description 2
- 208000008589 Obesity Diseases 0.000 claims description 2
- 239000007868 Raney catalyst Substances 0.000 claims description 2
- NPXOKRUENSOPAO-UHFFFAOYSA-N Raney nickel Chemical compound [Al].[Ni] NPXOKRUENSOPAO-UHFFFAOYSA-N 0.000 claims description 2
- 229910000564 Raney nickel Inorganic materials 0.000 claims description 2
- UIIMBOGNXHQVGW-DEQYMQKBSA-M Sodium bicarbonate-14C Chemical compound [Na+].O[14C]([O-])=O UIIMBOGNXHQVGW-DEQYMQKBSA-M 0.000 claims description 2
- 239000012317 TBTU Substances 0.000 claims description 2
- 229910021626 Tin(II) chloride Inorganic materials 0.000 claims description 2
- HCHKCACWOHOZIP-UHFFFAOYSA-N Zinc Chemical compound [Zn] HCHKCACWOHOZIP-UHFFFAOYSA-N 0.000 claims description 2
- CLZISMQKJZCZDN-UHFFFAOYSA-N [benzotriazol-1-yloxy(dimethylamino)methylidene]-dimethylazanium Chemical compound C1=CC=C2N(OC(N(C)C)=[N+](C)C)N=NC2=C1 CLZISMQKJZCZDN-UHFFFAOYSA-N 0.000 claims description 2
- 201000000690 abdominal obesity-metabolic syndrome Diseases 0.000 claims description 2
- 239000002253 acid Substances 0.000 claims description 2
- 230000009435 amidation Effects 0.000 claims description 2
- 238000007112 amidation reaction Methods 0.000 claims description 2
- 235000019270 ammonium chloride Nutrition 0.000 claims description 2
- 150000008064 anhydrides Chemical class 0.000 claims description 2
- 239000000010 aprotic solvent Substances 0.000 claims description 2
- 235000019445 benzyl alcohol Nutrition 0.000 claims description 2
- 150000001277 beta hydroxy acids Chemical class 0.000 claims description 2
- 229910052799 carbon Inorganic materials 0.000 claims description 2
- 230000000747 cardiac effect Effects 0.000 claims description 2
- 208000029078 coronary artery disease Diseases 0.000 claims description 2
- 125000000582 cycloheptyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000000113 cyclohexyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C([H])([H])C1([H])[H] 0.000 claims description 2
- 125000001511 cyclopentyl group Chemical group [H]C1([H])C([H])([H])C([H])([H])C([H])(*)C1([H])[H] 0.000 claims description 2
- 208000033679 diabetic kidney disease Diseases 0.000 claims description 2
- 125000000532 dioxanyl group Chemical group 0.000 claims description 2
- IKDUDTNKRLTJSI-UHFFFAOYSA-N hydrazine monohydrate Substances O.NN IKDUDTNKRLTJSI-UHFFFAOYSA-N 0.000 claims description 2
- 150000002431 hydrogen Chemical group 0.000 claims description 2
- 230000003451 hyperinsulinaemic effect Effects 0.000 claims description 2
- 201000008980 hyperinsulinism Diseases 0.000 claims description 2
- 239000012442 inert solvent Substances 0.000 claims description 2
- 125000001972 isopentyl group Chemical group [H]C([H])([H])C([H])(C([H])([H])[H])C([H])([H])C([H])([H])* 0.000 claims description 2
- UKVIEHSSVKSQBA-UHFFFAOYSA-N methane;palladium Chemical group C.[Pd] UKVIEHSSVKSQBA-UHFFFAOYSA-N 0.000 claims description 2
- 208000010125 myocardial infarction Diseases 0.000 claims description 2
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims description 2
- 125000001971 neopentyl group Chemical group [H]C([*])([H])C(C([H])([H])[H])(C([H])([H])[H])C([H])([H])[H] 0.000 claims description 2
- 230000004770 neurodegeneration Effects 0.000 claims description 2
- 125000002560 nitrile group Chemical group 0.000 claims description 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims description 2
- 235000020824 obesity Nutrition 0.000 claims description 2
- 239000011736 potassium bicarbonate Substances 0.000 claims description 2
- 235000015497 potassium bicarbonate Nutrition 0.000 claims description 2
- 229910000028 potassium bicarbonate Inorganic materials 0.000 claims description 2
- 229910000027 potassium carbonate Inorganic materials 0.000 claims description 2
- 235000011181 potassium carbonates Nutrition 0.000 claims description 2
- TYJJADVDDVDEDZ-UHFFFAOYSA-M potassium hydrogencarbonate Chemical compound [K+].OC([O-])=O TYJJADVDDVDEDZ-UHFFFAOYSA-M 0.000 claims description 2
- BDERNNFJNOPAEC-UHFFFAOYSA-N propan-1-ol Chemical compound CCCO BDERNNFJNOPAEC-UHFFFAOYSA-N 0.000 claims description 2
- 230000009467 reduction Effects 0.000 claims description 2
- 125000002914 sec-butyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(*)C([H])([H])[H] 0.000 claims description 2
- 229910000029 sodium carbonate Inorganic materials 0.000 claims description 2
- 235000017550 sodium carbonate Nutrition 0.000 claims description 2
- 239000001119 stannous chloride Substances 0.000 claims description 2
- 235000011150 stannous chloride Nutrition 0.000 claims description 2
- YZZHTKQARIXAQT-UHFFFAOYSA-N 1,4-dioxane;oxane Chemical compound C1CCOCC1.C1COCCO1 YZZHTKQARIXAQT-UHFFFAOYSA-N 0.000 claims 1
- 239000000463 material Substances 0.000 claims 1
- 208000015122 neurodegenerative disease Diseases 0.000 claims 1
- 230000033764 rhythmic process Effects 0.000 claims 1
- 229940079593 drug Drugs 0.000 abstract description 8
- 230000006371 metabolic abnormality Effects 0.000 abstract 1
- XEKOWRVHYACXOJ-UHFFFAOYSA-N Ethyl acetate Chemical compound CCOC(C)=O XEKOWRVHYACXOJ-UHFFFAOYSA-N 0.000 description 102
- 239000000243 solution Substances 0.000 description 46
- RTZKZFJDLAIYFH-UHFFFAOYSA-N Diethyl ether Chemical compound CCOCC RTZKZFJDLAIYFH-UHFFFAOYSA-N 0.000 description 44
- 238000006243 chemical reaction Methods 0.000 description 35
- 238000002330 electrospray ionisation mass spectrometry Methods 0.000 description 33
- 239000007787 solid Substances 0.000 description 33
- 238000005160 1H NMR spectroscopy Methods 0.000 description 32
- 238000001644 13C nuclear magnetic resonance spectroscopy Methods 0.000 description 29
- 238000003756 stirring Methods 0.000 description 27
- 239000003208 petroleum Substances 0.000 description 22
- 238000001914 filtration Methods 0.000 description 21
- 238000010898 silica gel chromatography Methods 0.000 description 21
- KDLHZDBZIXYQEI-UHFFFAOYSA-N Palladium Chemical compound [Pd] KDLHZDBZIXYQEI-UHFFFAOYSA-N 0.000 description 20
- FAPWRFPIFSIZLT-UHFFFAOYSA-M Sodium chloride Chemical class [Na+].[Cl-] FAPWRFPIFSIZLT-UHFFFAOYSA-M 0.000 description 20
- 239000012074 organic phase Substances 0.000 description 18
- 241001274216 Naso Species 0.000 description 17
- 239000008280 blood Substances 0.000 description 15
- 210000004369 blood Anatomy 0.000 description 15
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 15
- 230000002861 ventricular Effects 0.000 description 14
- 241000699670 Mus sp. Species 0.000 description 12
- SVIKHLOGVRDSGQ-UHFFFAOYSA-N 2-hydroxy-5-nitrobenzamide Chemical compound NC(=O)C1=CC([N+]([O-])=O)=CC=C1O SVIKHLOGVRDSGQ-UHFFFAOYSA-N 0.000 description 11
- WQZGKKKJIJFFOK-GASJEMHNSA-N Glucose Natural products OC[C@H]1OC(O)[C@H](O)[C@@H](O)[C@@H]1O WQZGKKKJIJFFOK-GASJEMHNSA-N 0.000 description 11
- 239000008103 glucose Substances 0.000 description 11
- 238000001953 recrystallisation Methods 0.000 description 11
- FUQOTYRCMBZFOL-UHFFFAOYSA-N 5-chloro-1H-indole-2-carboxylic acid Chemical compound ClC1=CC=C2NC(C(=O)O)=CC2=C1 FUQOTYRCMBZFOL-UHFFFAOYSA-N 0.000 description 10
- 102000007390 Glycogen Phosphorylase Human genes 0.000 description 10
- 108010046163 Glycogen Phosphorylase Proteins 0.000 description 10
- 229920006395 saturated elastomer Polymers 0.000 description 10
- 241000699666 Mus <mouse, genus> Species 0.000 description 9
- 230000002440 hepatic effect Effects 0.000 description 9
- 210000002216 heart Anatomy 0.000 description 8
- 230000002401 inhibitory effect Effects 0.000 description 8
- 230000000694 effects Effects 0.000 description 7
- QTBSBXVTEAMEQO-UHFFFAOYSA-N Acetic acid Chemical compound CC(O)=O QTBSBXVTEAMEQO-UHFFFAOYSA-N 0.000 description 6
- HEMHJVSKTPXQMS-UHFFFAOYSA-M Sodium hydroxide Chemical compound [OH-].[Na+] HEMHJVSKTPXQMS-UHFFFAOYSA-M 0.000 description 6
- RYYVLZVUVIJVGH-UHFFFAOYSA-N caffeine Chemical compound CN1C(=O)N(C)C(=O)C2=C1N=CN2C RYYVLZVUVIJVGH-UHFFFAOYSA-N 0.000 description 6
- 210000000038 chest Anatomy 0.000 description 6
- 210000005240 left ventricle Anatomy 0.000 description 6
- 238000012360 testing method Methods 0.000 description 6
- 239000012141 concentrate Substances 0.000 description 5
- ZHNUHDYFZUAESO-UHFFFAOYSA-N formamide Substances NC=O ZHNUHDYFZUAESO-UHFFFAOYSA-N 0.000 description 5
- 238000002604 ultrasonography Methods 0.000 description 5
- HEDRZPFGACZZDS-MICDWDOJSA-N Trichloro(2H)methane Chemical compound [2H]C(Cl)(Cl)Cl HEDRZPFGACZZDS-MICDWDOJSA-N 0.000 description 4
- 230000005764 inhibitory process Effects 0.000 description 4
- 239000000523 sample Substances 0.000 description 4
- 238000004904 shortening Methods 0.000 description 4
- CSCPPACGZOOCGX-UHFFFAOYSA-N Acetone Chemical compound CC(C)=O CSCPPACGZOOCGX-UHFFFAOYSA-N 0.000 description 3
- LPHGQDQBBGAPDZ-UHFFFAOYSA-N Isocaffeine Natural products CN1C(=O)N(C)C(=O)C2=C1N(C)C=N2 LPHGQDQBBGAPDZ-UHFFFAOYSA-N 0.000 description 3
- 241001465754 Metazoa Species 0.000 description 3
- OFOBLEOULBTSOW-UHFFFAOYSA-N Propanedioic acid Natural products OC(=O)CC(O)=O OFOBLEOULBTSOW-UHFFFAOYSA-N 0.000 description 3
- ZTQSAGDEMFDKMZ-UHFFFAOYSA-N butyric aldehyde Natural products CCCC=O ZTQSAGDEMFDKMZ-UHFFFAOYSA-N 0.000 description 3
- 229960001948 caffeine Drugs 0.000 description 3
- VJEONQKOZGKCAK-UHFFFAOYSA-N caffeine Natural products CN1C(=O)N(C)C(=O)C2=C1C=CN2C VJEONQKOZGKCAK-UHFFFAOYSA-N 0.000 description 3
- 230000015556 catabolic process Effects 0.000 description 3
- KRKNYBCHXYNGOX-UHFFFAOYSA-N citric acid Chemical compound OC(=O)CC(O)(C(O)=O)CC(O)=O KRKNYBCHXYNGOX-UHFFFAOYSA-N 0.000 description 3
- 238000006731 degradation reaction Methods 0.000 description 3
- 230000003205 diastolic effect Effects 0.000 description 3
- 231100000673 dose–response relationship Toxicity 0.000 description 3
- 238000000605 extraction Methods 0.000 description 3
- 238000009472 formulation Methods 0.000 description 3
- 230000009229 glucose formation Effects 0.000 description 3
- 235000009200 high fat diet Nutrition 0.000 description 3
- XZWYZXLIPXDOLR-UHFFFAOYSA-N metformin Chemical compound CN(C)C(=N)NC(N)=N XZWYZXLIPXDOLR-UHFFFAOYSA-N 0.000 description 3
- 210000003205 muscle Anatomy 0.000 description 3
- HGBOYTHUEUWSSQ-UHFFFAOYSA-N valeric aldehyde Natural products CCCCC=O HGBOYTHUEUWSSQ-UHFFFAOYSA-N 0.000 description 3
- JKMHFZQWWAIEOD-UHFFFAOYSA-N 2-[4-(2-hydroxyethyl)piperazin-1-yl]ethanesulfonic acid Chemical compound OCC[NH+]1CCN(CCS([O-])(=O)=O)CC1 JKMHFZQWWAIEOD-UHFFFAOYSA-N 0.000 description 2
- HCFAJYNVAYBARA-UHFFFAOYSA-N 4-heptanone Chemical compound CCCC(=O)CCC HCFAJYNVAYBARA-UHFFFAOYSA-N 0.000 description 2
- IKHGUXGNUITLKF-UHFFFAOYSA-N Acetaldehyde Chemical compound CC=O IKHGUXGNUITLKF-UHFFFAOYSA-N 0.000 description 2
- RGHNJXZEOKUKBD-SQOUGZDYSA-N D-gluconic acid Chemical compound OC[C@@H](O)[C@@H](O)[C@H](O)[C@@H](O)C(O)=O RGHNJXZEOKUKBD-SQOUGZDYSA-N 0.000 description 2
- 102000004190 Enzymes Human genes 0.000 description 2
- 108090000790 Enzymes Proteins 0.000 description 2
- VZCYOOQTPOCHFL-OWOJBTEDSA-N Fumaric acid Chemical compound OC(=O)\C=C\C(O)=O VZCYOOQTPOCHFL-OWOJBTEDSA-N 0.000 description 2
- ZFEGAPGPTKYYRM-UHFFFAOYSA-N NC(C=C1)=CC2=C1OC1(CCCC1)NC2=O Chemical compound NC(C=C1)=CC2=C1OC1(CCCC1)NC2=O ZFEGAPGPTKYYRM-UHFFFAOYSA-N 0.000 description 2
- 238000005481 NMR spectroscopy Methods 0.000 description 2
- 241000283973 Oryctolagus cuniculus Species 0.000 description 2
- NBIIXXVUZAFLBC-UHFFFAOYSA-N Phosphoric acid Chemical compound OP(O)(O)=O NBIIXXVUZAFLBC-UHFFFAOYSA-N 0.000 description 2
- NBBJYMSMWIIQGU-UHFFFAOYSA-N Propionic aldehyde Chemical compound CCC=O NBBJYMSMWIIQGU-UHFFFAOYSA-N 0.000 description 2
- 241000700159 Rattus Species 0.000 description 2
- PMZURENOXWZQFD-UHFFFAOYSA-L Sodium Sulfate Chemical compound [Na+].[Na+].[O-]S([O-])(=O)=O PMZURENOXWZQFD-UHFFFAOYSA-L 0.000 description 2
- DTQVDTLACAAQTR-UHFFFAOYSA-N Trifluoroacetic acid Chemical compound OC(=O)C(F)(F)F DTQVDTLACAAQTR-UHFFFAOYSA-N 0.000 description 2
- UBOJPUMWECONLK-UHFFFAOYSA-N [O-][N+](C(C=C1)=CC2=C1OC1(CCCC1)NC2=O)=O Chemical compound [O-][N+](C(C=C1)=CC2=C1OC1(CCCC1)NC2=O)=O UBOJPUMWECONLK-UHFFFAOYSA-N 0.000 description 2
- RSHMTPFPHQNJJI-UHFFFAOYSA-N [O-][N+](C(C=C1)=CC2=C1OC1(CCCCC1)NC2=O)=O Chemical compound [O-][N+](C(C=C1)=CC2=C1OC1(CCCCC1)NC2=O)=O RSHMTPFPHQNJJI-UHFFFAOYSA-N 0.000 description 2
- 235000011054 acetic acid Nutrition 0.000 description 2
- VZTDIZULWFCMLS-UHFFFAOYSA-N ammonium formate Chemical compound [NH4+].[O-]C=O VZTDIZULWFCMLS-UHFFFAOYSA-N 0.000 description 2
- 239000003472 antidiabetic agent Substances 0.000 description 2
- 125000003943 azolyl group Chemical group 0.000 description 2
- WPYMKLBDIGXBTP-UHFFFAOYSA-N benzoic acid Chemical compound OC(=O)C1=CC=CC=C1 WPYMKLBDIGXBTP-UHFFFAOYSA-N 0.000 description 2
- 230000036770 blood supply Effects 0.000 description 2
- JHIVVAPYMSGYDF-UHFFFAOYSA-N cyclohexanone Chemical compound O=C1CCCCC1 JHIVVAPYMSGYDF-UHFFFAOYSA-N 0.000 description 2
- BGTOWKSIORTVQH-UHFFFAOYSA-N cyclopentanone Chemical compound O=C1CCCC1 BGTOWKSIORTVQH-UHFFFAOYSA-N 0.000 description 2
- XBDQKXXYIPTUBI-UHFFFAOYSA-N dimethylselenoniopropionate Natural products CCC(O)=O XBDQKXXYIPTUBI-UHFFFAOYSA-N 0.000 description 2
- 239000002552 dosage form Substances 0.000 description 2
- 150000002148 esters Chemical class 0.000 description 2
- DEFVIWRASFVYLL-UHFFFAOYSA-N ethylene glycol bis(2-aminoethyl)tetraacetic acid Chemical compound OC(=O)CN(CC(O)=O)CCOCCOCCN(CC(O)=O)CC(O)=O DEFVIWRASFVYLL-UHFFFAOYSA-N 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 238000003304 gavage Methods 0.000 description 2
- 230000004110 gluconeogenesis Effects 0.000 description 2
- 230000004116 glycogenolysis Effects 0.000 description 2
- 229940093915 gynecological organic acid Drugs 0.000 description 2
- 238000004128 high performance liquid chromatography Methods 0.000 description 2
- 238000002347 injection Methods 0.000 description 2
- 239000007924 injection Substances 0.000 description 2
- 230000003601 intercostal effect Effects 0.000 description 2
- TWBYWOBDOCUKOW-UHFFFAOYSA-N isonicotinic acid Chemical compound OC(=O)C1=CC=NC=C1 TWBYWOBDOCUKOW-UHFFFAOYSA-N 0.000 description 2
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 2
- 229960003105 metformin Drugs 0.000 description 2
- 230000004048 modification Effects 0.000 description 2
- 238000012986 modification Methods 0.000 description 2
- 235000005985 organic acids Nutrition 0.000 description 2
- 239000012044 organic layer Substances 0.000 description 2
- FDPIMTJIUBPUKL-UHFFFAOYSA-N pentan-3-one Chemical compound CCC(=O)CC FDPIMTJIUBPUKL-UHFFFAOYSA-N 0.000 description 2
- 239000012071 phase Substances 0.000 description 2
- WLJVNTCWHIRURA-UHFFFAOYSA-N pimelic acid Chemical compound OC(=O)CCCCCC(O)=O WLJVNTCWHIRURA-UHFFFAOYSA-N 0.000 description 2
- 239000013641 positive control Substances 0.000 description 2
- 230000002265 prevention Effects 0.000 description 2
- 239000006228 supernatant Substances 0.000 description 2
- 239000000725 suspension Substances 0.000 description 2
- 210000000115 thoracic cavity Anatomy 0.000 description 2
- VZCYOOQTPOCHFL-UHFFFAOYSA-N trans-butenedioic acid Natural products OC(=O)C=CC(O)=O VZCYOOQTPOCHFL-UHFFFAOYSA-N 0.000 description 2
- NQPDZGIKBAWPEJ-UHFFFAOYSA-N valeric acid Chemical compound CCCCC(O)=O NQPDZGIKBAWPEJ-UHFFFAOYSA-N 0.000 description 2
- JWZZKOKVBUJMES-UHFFFAOYSA-N (+-)-Isoprenaline Chemical compound CC(C)NCC(O)C1=CC=C(O)C(O)=C1 JWZZKOKVBUJMES-UHFFFAOYSA-N 0.000 description 1
- BJEPYKJPYRNKOW-REOHCLBHSA-N (S)-malic acid Chemical compound OC(=O)[C@@H](O)CC(O)=O BJEPYKJPYRNKOW-REOHCLBHSA-N 0.000 description 1
- XVMIKRZPDSXBTP-UHFFFAOYSA-N 1,3-dibromobutan-2-one Chemical compound CC(Br)C(=O)CBr XVMIKRZPDSXBTP-UHFFFAOYSA-N 0.000 description 1
- DQFQCHIDRBIESA-UHFFFAOYSA-N 1-benzazepine Chemical compound N1C=CC=CC2=CC=CC=C12 DQFQCHIDRBIESA-UHFFFAOYSA-N 0.000 description 1
- OXQGTIUCKGYOAA-UHFFFAOYSA-N 2-Ethylbutanoic acid Chemical compound CCC(CC)C(O)=O OXQGTIUCKGYOAA-UHFFFAOYSA-N 0.000 description 1
- LBLYYCQCTBFVLH-UHFFFAOYSA-N 2-Methylbenzenesulfonic acid Chemical compound CC1=CC=CC=C1S(O)(=O)=O LBLYYCQCTBFVLH-UHFFFAOYSA-N 0.000 description 1
- BMYNFMYTOJXKLE-UHFFFAOYSA-N 3-azaniumyl-2-hydroxypropanoate Chemical compound NCC(O)C(O)=O BMYNFMYTOJXKLE-UHFFFAOYSA-N 0.000 description 1
- MIJRRMLODIKPEA-UHFFFAOYSA-N 5-chloro-1h-pyrrolo[2,3-c]pyridine-2-carboxylic acid Chemical compound ClC1=NC=C2NC(C(=O)O)=CC2=C1 MIJRRMLODIKPEA-UHFFFAOYSA-N 0.000 description 1
- ZCYVEMRRCGMTRW-UHFFFAOYSA-N 7553-56-2 Chemical compound [I] ZCYVEMRRCGMTRW-UHFFFAOYSA-N 0.000 description 1
- CIWBSHSKHKDKBQ-JLAZNSOCSA-N Ascorbic acid Natural products OC[C@H](O)[C@H]1OC(=O)C(O)=C1O CIWBSHSKHKDKBQ-JLAZNSOCSA-N 0.000 description 1
- 239000005711 Benzoic acid Substances 0.000 description 1
- WKBOTKDWSSQWDR-UHFFFAOYSA-N Bromine atom Chemical compound [Br] WKBOTKDWSSQWDR-UHFFFAOYSA-N 0.000 description 1
- FBZMKKCHUGPPOG-UHFFFAOYSA-N C(Cl)Cl.O1CCCCC1 Chemical compound C(Cl)Cl.O1CCCCC1 FBZMKKCHUGPPOG-UHFFFAOYSA-N 0.000 description 1
- 238000011740 C57BL/6 mouse Methods 0.000 description 1
- 238000011746 C57BL/6J (JAX™ mouse strain) Methods 0.000 description 1
- VGBYAHQXOKJKOX-UHFFFAOYSA-N CCC(CC)(N1)OC(C=CC(N)=C2)=C2C1=O Chemical compound CCC(CC)(N1)OC(C=CC(N)=C2)=C2C1=O VGBYAHQXOKJKOX-UHFFFAOYSA-N 0.000 description 1
- FSRYZRNUZMCGJT-UHFFFAOYSA-N CCCC(CCC)(N1)OC(C=CC(N)=C2)=C2C1=O Chemical compound CCCC(CCC)(N1)OC(C=CC(N)=C2)=C2C1=O FSRYZRNUZMCGJT-UHFFFAOYSA-N 0.000 description 1
- ZAMOUSCENKQFHK-UHFFFAOYSA-N Chlorine atom Chemical compound [Cl] ZAMOUSCENKQFHK-UHFFFAOYSA-N 0.000 description 1
- 229920000742 Cotton Polymers 0.000 description 1
- NBSCHQHZLSJFNQ-GASJEMHNSA-N D-Glucose 6-phosphate Chemical compound OC1O[C@H](COP(O)(O)=O)[C@@H](O)[C@H](O)[C@H]1O NBSCHQHZLSJFNQ-GASJEMHNSA-N 0.000 description 1
- RGHNJXZEOKUKBD-UHFFFAOYSA-N D-gluconic acid Natural products OCC(O)C(O)C(O)C(O)C(O)=O RGHNJXZEOKUKBD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-JCYAYHJZSA-N Dextrotartaric acid Chemical compound OC(=O)[C@H](O)[C@@H](O)C(O)=O FEWJPZIEWOKRBE-JCYAYHJZSA-N 0.000 description 1
- IAZDPXIOMUYVGZ-WFGJKAKNSA-N Dimethyl sulfoxide Chemical compound [2H]C([2H])([2H])S(=O)C([2H])([2H])[2H] IAZDPXIOMUYVGZ-WFGJKAKNSA-N 0.000 description 1
- PXGOKWXKJXAPGV-UHFFFAOYSA-N Fluorine Chemical compound FF PXGOKWXKJXAPGV-UHFFFAOYSA-N 0.000 description 1
- VFRROHXSMXFLSN-UHFFFAOYSA-N Glc6P Natural products OP(=O)(O)OCC(O)C(O)C(O)C(O)C=O VFRROHXSMXFLSN-UHFFFAOYSA-N 0.000 description 1
- 102000003638 Glucose-6-Phosphatase Human genes 0.000 description 1
- 108010086800 Glucose-6-Phosphatase Proteins 0.000 description 1
- 206010019280 Heart failures Diseases 0.000 description 1
- PIWKPBJCKXDKJR-UHFFFAOYSA-N Isoflurane Chemical compound FC(F)OC(Cl)C(F)(F)F PIWKPBJCKXDKJR-UHFFFAOYSA-N 0.000 description 1
- CJUJTQVFFAEALL-UHFFFAOYSA-N NC(C=C1)=CC2=C1OC1(CCCCC1)NC2=O Chemical compound NC(C=C1)=CC2=C1OC1(CCCCC1)NC2=O CJUJTQVFFAEALL-UHFFFAOYSA-N 0.000 description 1
- WOLVODDDUIGUOF-UHFFFAOYSA-N NC=1C=CC2=C(C(NC(O2)(C)C)=O)C1 Chemical compound NC=1C=CC2=C(C(NC(O2)(C)C)=O)C1 WOLVODDDUIGUOF-UHFFFAOYSA-N 0.000 description 1
- PVNIIMVLHYAWGP-UHFFFAOYSA-N Niacin Chemical compound OC(=O)C1=CC=CN=C1 PVNIIMVLHYAWGP-UHFFFAOYSA-N 0.000 description 1
- GRYLNZFGIOXLOG-UHFFFAOYSA-N Nitric acid Chemical compound O[N+]([O-])=O GRYLNZFGIOXLOG-UHFFFAOYSA-N 0.000 description 1
- 206010063837 Reperfusion injury Diseases 0.000 description 1
- KDYFGRWQOYBRFD-UHFFFAOYSA-N Succinic acid Natural products OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 description 1
- FEWJPZIEWOKRBE-UHFFFAOYSA-N Tartaric acid Natural products [H+].[H+].[O-]C(=O)C(O)C(O)C([O-])=O FEWJPZIEWOKRBE-UHFFFAOYSA-N 0.000 description 1
- ATJFFYVFTNAWJD-UHFFFAOYSA-N Tin Chemical compound [Sn] ATJFFYVFTNAWJD-UHFFFAOYSA-N 0.000 description 1
- 230000002378 acidificating effect Effects 0.000 description 1
- 239000002671 adjuvant Substances 0.000 description 1
- HXXFSFRBOHSIMQ-VFUOTHLCSA-N alpha-D-glucose 1-phosphate Chemical compound OC[C@H]1O[C@H](OP(O)(O)=O)[C@H](O)[C@@H](O)[C@@H]1O HXXFSFRBOHSIMQ-VFUOTHLCSA-N 0.000 description 1
- BJEPYKJPYRNKOW-UHFFFAOYSA-N alpha-hydroxysuccinic acid Natural products OC(=O)C(O)CC(O)=O BJEPYKJPYRNKOW-UHFFFAOYSA-N 0.000 description 1
- 229910000147 aluminium phosphate Inorganic materials 0.000 description 1
- 239000011609 ammonium molybdate Substances 0.000 description 1
- APUPEJJSWDHEBO-UHFFFAOYSA-P ammonium molybdate Chemical compound [NH4+].[NH4+].[O-][Mo]([O-])(=O)=O APUPEJJSWDHEBO-UHFFFAOYSA-P 0.000 description 1
- 235000018660 ammonium molybdate Nutrition 0.000 description 1
- 229940010552 ammonium molybdate Drugs 0.000 description 1
- 238000010171 animal model Methods 0.000 description 1
- 125000002178 anthracenyl group Chemical group C1(=CC=CC2=CC3=CC=CC=C3C=C12)* 0.000 description 1
- 229940127003 anti-diabetic drug Drugs 0.000 description 1
- 239000003963 antioxidant agent Substances 0.000 description 1
- 235000006708 antioxidants Nutrition 0.000 description 1
- 206010003119 arrhythmia Diseases 0.000 description 1
- 230000006793 arrhythmia Effects 0.000 description 1
- 210000001367 artery Anatomy 0.000 description 1
- 235000010323 ascorbic acid Nutrition 0.000 description 1
- 239000011668 ascorbic acid Substances 0.000 description 1
- 229960005070 ascorbic acid Drugs 0.000 description 1
- 230000009286 beneficial effect Effects 0.000 description 1
- SRSXLGNVWSONIS-UHFFFAOYSA-N benzenesulfonic acid Chemical compound OS(=O)(=O)C1=CC=CC=C1 SRSXLGNVWSONIS-UHFFFAOYSA-N 0.000 description 1
- 229940092714 benzenesulfonic acid Drugs 0.000 description 1
- 125000005605 benzo group Chemical group 0.000 description 1
- 235000010233 benzoic acid Nutrition 0.000 description 1
- 239000011230 binding agent Substances 0.000 description 1
- 230000037396 body weight Effects 0.000 description 1
- GDTBXPJZTBHREO-UHFFFAOYSA-N bromine Substances BrBr GDTBXPJZTBHREO-UHFFFAOYSA-N 0.000 description 1
- 239000007853 buffer solution Substances 0.000 description 1
- KDYFGRWQOYBRFD-NUQCWPJISA-N butanedioic acid Chemical compound O[14C](=O)CC[14C](O)=O KDYFGRWQOYBRFD-NUQCWPJISA-N 0.000 description 1
- 125000000484 butyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])C([H])([H])[H] 0.000 description 1
- 238000004364 calculation method Methods 0.000 description 1
- 239000002775 capsule Substances 0.000 description 1
- 235000015165 citric acid Nutrition 0.000 description 1
- 238000004737 colorimetric analysis Methods 0.000 description 1
- 230000008602 contraction Effects 0.000 description 1
- 239000013068 control sample Substances 0.000 description 1
- 238000001816 cooling Methods 0.000 description 1
- 210000004351 coronary vessel Anatomy 0.000 description 1
- 230000009193 crawling Effects 0.000 description 1
- 239000006071 cream Substances 0.000 description 1
- 230000002951 depilatory effect Effects 0.000 description 1
- 238000013461 design Methods 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 239000003085 diluting agent Substances 0.000 description 1
- 239000007884 disintegrant Substances 0.000 description 1
- 239000002270 dispersing agent Substances 0.000 description 1
- CCIVGXIOQKPBKL-UHFFFAOYSA-M ethanesulfonate Chemical compound CCS([O-])(=O)=O CCIVGXIOQKPBKL-UHFFFAOYSA-M 0.000 description 1
- 125000004494 ethyl ester group Chemical group 0.000 description 1
- 238000011156 evaluation Methods 0.000 description 1
- 239000000945 filler Substances 0.000 description 1
- 239000000796 flavoring agent Substances 0.000 description 1
- 235000019634 flavors Nutrition 0.000 description 1
- 239000011737 fluorine Substances 0.000 description 1
- 235000013305 food Nutrition 0.000 description 1
- 239000001530 fumaric acid Substances 0.000 description 1
- 235000011087 fumaric acid Nutrition 0.000 description 1
- 125000002541 furyl group Chemical group 0.000 description 1
- 239000000174 gluconic acid Substances 0.000 description 1
- 235000012208 gluconic acid Nutrition 0.000 description 1
- 229950010772 glucose-1-phosphate Drugs 0.000 description 1
- 229940045189 glucose-6-phosphate Drugs 0.000 description 1
- 239000002874 hemostatic agent Substances 0.000 description 1
- 125000005842 heteroatom Chemical group 0.000 description 1
- JARKCYVAAOWBJS-UHFFFAOYSA-N hexanal Chemical compound CCCCCC=O JARKCYVAAOWBJS-UHFFFAOYSA-N 0.000 description 1
- 230000002218 hypoglycaemic effect Effects 0.000 description 1
- 125000002883 imidazolyl group Chemical group 0.000 description 1
- 230000006872 improvement Effects 0.000 description 1
- 238000000338 in vitro Methods 0.000 description 1
- 238000001727 in vivo Methods 0.000 description 1
- 125000001041 indolyl group Chemical group 0.000 description 1
- 238000009413 insulation Methods 0.000 description 1
- 210000000876 intercostal muscle Anatomy 0.000 description 1
- 239000011630 iodine Substances 0.000 description 1
- 208000028867 ischemia Diseases 0.000 description 1
- 229960002725 isoflurane Drugs 0.000 description 1
- 125000002183 isoquinolinyl group Chemical group C1(=NC=CC2=CC=CC=C12)* 0.000 description 1
- 210000004731 jugular vein Anatomy 0.000 description 1
- 150000002576 ketones Chemical class 0.000 description 1
- TYQCGQRIZGCHNB-JLAZNSOCSA-N l-ascorbic acid Chemical compound OC[C@H](O)[C@H]1OC(O)=C(O)C1=O TYQCGQRIZGCHNB-JLAZNSOCSA-N 0.000 description 1
- 239000004310 lactic acid Substances 0.000 description 1
- 235000014655 lactic acid Nutrition 0.000 description 1
- 239000007788 liquid Substances 0.000 description 1
- 210000004185 liver Anatomy 0.000 description 1
- 235000015263 low fat diet Nutrition 0.000 description 1
- 239000000314 lubricant Substances 0.000 description 1
- FDZZZRQASAIRJF-UHFFFAOYSA-M malachite green Chemical compound [Cl-].C1=CC(N(C)C)=CC=C1C(C=1C=CC=CC=1)=C1C=CC(=[N+](C)C)C=C1 FDZZZRQASAIRJF-UHFFFAOYSA-M 0.000 description 1
- 229940107698 malachite green Drugs 0.000 description 1
- 238000013227 male C57BL/6J mice Methods 0.000 description 1
- VZCYOOQTPOCHFL-UPHRSURJSA-N maleic acid Chemical compound OC(=O)\C=C/C(O)=O VZCYOOQTPOCHFL-UPHRSURJSA-N 0.000 description 1
- 239000011976 maleic acid Substances 0.000 description 1
- 239000001630 malic acid Substances 0.000 description 1
- 235000011090 malic acid Nutrition 0.000 description 1
- UUBFELFUKFJSRD-UHFFFAOYSA-N methyl 2-hydroxy-5-nitrobenzoate Chemical compound COC(=O)C1=CC([N+]([O-])=O)=CC=C1O UUBFELFUKFJSRD-UHFFFAOYSA-N 0.000 description 1
- 238000010172 mouse model Methods 0.000 description 1
- 230000002107 myocardial effect Effects 0.000 description 1
- 210000004165 myocardium Anatomy 0.000 description 1
- UJYAZVSPFMJCLW-UHFFFAOYSA-N n-(oxomethylidene)benzenesulfonamide Chemical compound O=C=NS(=O)(=O)C1=CC=CC=C1 UJYAZVSPFMJCLW-UHFFFAOYSA-N 0.000 description 1
- YZMHQCWXYHARLS-UHFFFAOYSA-N naphthalene-1,2-disulfonic acid Chemical compound C1=CC=CC2=C(S(O)(=O)=O)C(S(=O)(=O)O)=CC=C21 YZMHQCWXYHARLS-UHFFFAOYSA-N 0.000 description 1
- 235000001968 nicotinic acid Nutrition 0.000 description 1
- 239000011664 nicotinic acid Substances 0.000 description 1
- 229960003512 nicotinic acid Drugs 0.000 description 1
- 229910017604 nitric acid Inorganic materials 0.000 description 1
- 238000013116 obese mouse model Methods 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 210000000062 pectoralis major Anatomy 0.000 description 1
- 210000000989 pectoralis minor Anatomy 0.000 description 1
- 239000000546 pharmaceutical excipient Substances 0.000 description 1
- 230000000144 pharmacologic effect Effects 0.000 description 1
- 125000005561 phenanthryl group Chemical group 0.000 description 1
- 230000026731 phosphorylation Effects 0.000 description 1
- 238000006366 phosphorylation reaction Methods 0.000 description 1
- 239000006187 pill Substances 0.000 description 1
- 239000003755 preservative agent Substances 0.000 description 1
- 230000008569 process Effects 0.000 description 1
- 235000019260 propionic acid Nutrition 0.000 description 1
- 230000001681 protective effect Effects 0.000 description 1
- 125000003373 pyrazinyl group Chemical group 0.000 description 1
- 125000002098 pyridazinyl group Chemical group 0.000 description 1
- 125000004076 pyridyl group Chemical group 0.000 description 1
- 125000000714 pyrimidinyl group Chemical group 0.000 description 1
- 125000000168 pyrrolyl group Chemical group 0.000 description 1
- 125000002294 quinazolinyl group Chemical group N1=C(N=CC2=CC=CC=C12)* 0.000 description 1
- IUVKMZGDUIUOCP-BTNSXGMBSA-N quinbolone Chemical compound O([C@H]1CC[C@H]2[C@H]3[C@@H]([C@]4(C=CC(=O)C=C4CC3)C)CC[C@@]21C)C1=CCCC1 IUVKMZGDUIUOCP-BTNSXGMBSA-N 0.000 description 1
- 125000002943 quinolinyl group Chemical group N1=C(C=CC2=CC=CC=C12)* 0.000 description 1
- 239000011535 reaction buffer Substances 0.000 description 1
- 230000002829 reductive effect Effects 0.000 description 1
- 230000010410 reperfusion Effects 0.000 description 1
- 238000011160 research Methods 0.000 description 1
- 230000000284 resting effect Effects 0.000 description 1
- 210000005241 right ventricle Anatomy 0.000 description 1
- 230000028527 righting reflex Effects 0.000 description 1
- 239000007901 soft capsule Substances 0.000 description 1
- 239000002904 solvent Substances 0.000 description 1
- 239000000829 suppository Substances 0.000 description 1
- 239000003826 tablet Substances 0.000 description 1
- 239000011975 tartaric acid Substances 0.000 description 1
- 235000002906 tartaric acid Nutrition 0.000 description 1
- 125000000335 thiazolyl group Chemical group 0.000 description 1
- 125000001544 thienyl group Chemical group 0.000 description 1
- 229940005605 valeric acid Drugs 0.000 description 1
- 210000003462 vein Anatomy 0.000 description 1
- 238000005303 weighing Methods 0.000 description 1
- 239000000080 wetting agent Substances 0.000 description 1
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/536—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines ortho- or peri-condensed with carbocyclic ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/33—Heterocyclic compounds
- A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
- A61K31/535—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines
- A61K31/537—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with at least one nitrogen and one oxygen as the ring hetero atoms, e.g. 1,2-oxazines spiro-condensed or forming part of bridged ring systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P13/00—Drugs for disorders of the urinary system
- A61P13/12—Drugs for disorders of the urinary system of the kidneys
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P3/00—Drugs for disorders of the metabolism
- A61P3/08—Drugs for disorders of the metabolism for glucose homeostasis
- A61P3/10—Drugs for disorders of the metabolism for glucose homeostasis for hyperglycaemia, e.g. antidiabetics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/48—Drugs for disorders of the endocrine system of the pancreatic hormones
- A61P5/50—Drugs for disorders of the endocrine system of the pancreatic hormones for increasing or potentiating the activity of insulin
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
- A61P9/12—Antihypertensives
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D413/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms
- C07D413/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings
- C07D413/12—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and oxygen atoms as the only ring hetero atoms containing two hetero rings linked by a chain containing hetero atoms as chain links
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
- C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
- C07D471/04—Ortho-condensed systems
Definitions
- the invention relates to the field of medicinal chemistry, in particular to a benzoxazin-4-one compound as a glycogen phosphorylase inhibitor, a preparation method and medical use thereof.
- the liver is an important organ that regulates blood sugar in the fasted state. It is estimated that after an overnight fast, 74% of fasting blood glucose is derived from hepatic glycogenolysis and the remainder from hepatic gluconeogenesis. In patients with type 2 diabetes, the rate of hepatic glucose production is significantly increased, and hepatic glucose production is on the high side. Therefore, inhibition of hepatic glucose production has become one of the important targets for the development of new antidiabetic drugs.
- metformin the clinically preferred hypoglycemic drug
- inhibition of hepatic glycogen degradation, thereby reducing their hepatic glucose output helps to reduce their fasting blood glucose.
- Glycogen phosphorylase is a key enzyme that catalyzes glycogenolysis, which catalyzes the phosphorylation of glycogen, and the generated glucose-1-phosphate is converted into glucose- 6-phosphate, which is catalyzed by glucose-6-phosphatase to generate glucose, and blood sugar rises.
- glycogen phosphorylase thereby inhibiting hepatic glycogen degradation.
- CN103497181A discloses a benzazepine Ketones have good inhibitory activity on glycogen phosphorylase, but the problem is that their half-life in the body is too short, they will be metabolized by the body soon after taking the drug, and the bioavailability is low, which causes serious problems. affect the efficacy.
- the present invention provides a benzoxazinone compound represented by formula (I) with glycogen phosphorylase inhibitory activity, a preparation method and medical use thereof. Since the compound of formula (I) of the present invention can inhibit glycogen phosphorylase, it can be used for the prevention and/or treatment of diseases related to abnormal glycogen metabolism. In particular, the compounds of the present invention have a long half-life in vivo, high bioavailability, and improved curative effect.
- the present invention relates to a compound of formula (I) or a pharmaceutically acceptable salt thereof as follows:
- X 1 , X 2 , X 3 and X 4 are all C or one of X 1 , X 2 , X 3 and X 4 is N and the other must be C;
- R 1 and R 1 ' are each independently H, halogen, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl , ethynyl;
- R 2 and R 2 ' are each independently H, halogen, hydroxy, cyano, C 1-4 alkyl, C 1-4 alkoxy, fluoromethyl, difluoromethyl, trifluoromethyl, vinyl , ethynyl;
- R 3 is H, unsubstituted or X-substituted linear or branched alkyl of 1-20 carbons, unsubstituted or X-substituted linear or branched alkenyl of 2-20 carbons, 2-20 unsubstituted or X-substituted straight or branched chain alkynyl, unsubstituted or X-substituted aryl, unsubstituted or X-substituted heteroaryl;
- R 4 and R 5 are each independently H, unsubstituted or X-substituted linear or branched alkyl of 1-20 carbons, unsubstituted or X-substituted linear or branched alkene of 2-20 carbons base, 2-20 carbon unsubstituted or X-substituted linear or branched alkynyl, R 4 and R 5 can optionally form a ring;
- Y is CHR 6 , NH, O, S;
- R 6 is H, unsubstituted or X-substituted linear or branched alkyl of 1-20 carbons, unsubstituted or X-substituted linear or branched alkene of 2-20 carbons, 2-20 unsubstituted or X-substituted straight or branched chain alkynyl, phenyl, benzyl, naphthyl, nitrile groups of carbon atoms;
- X is F, Cl , Br, I, CN, NO2, NH2 , CF3 , SH, OH, OCH3 , OC2H5 , COOH, straight or branched chain alkyl of 1-10 carbons, 2 - Linear or branched alkenyl of 10 carbons, linear or branched alkynyl of 2-10 carbons, aryl, heteroaryl.
- X 1 , X 2 , X 3 and X 4 are all C or one of X 2 and X 3 is N and the other must be C;
- R 1 and R 1 ' are each independently H, halogen, cyano, C 1-4 alkoxy;
- R 2 and R 2 ' are each independently H;
- R 3 is H, unsubstituted or X-substituted linear or branched alkyl of 1-20 carbons, unsubstituted or X-substituted C 6-14 aryl, unsubstituted or X-substituted C 5-10 hetero Aryl;
- R 4 and R 5 are each independently H, unsubstituted or X-substituted linear or branched alkyl of 1-20 carbons, and R 4 and R 5 may optionally form a ring;
- Y is CH 2 , NH, O;
- X is F, Cl , Br, I, CN, NO2, NH2 , CF3 , SH, OH, OCH3 , OC2H5 , COOH, straight or branched chain alkyl of 1-10 carbons, 2 - Linear or branched alkenyl of 10 carbons, linear or branched alkynyl of 2 to 10 carbons, C6-14 aryl, C5-10 heteroaryl.
- X 1 , X 2 , X 3 and X 4 are all C or one of X 2 and X 3 is N and the other must be C;
- R 1 and R 1 ' are each independently H, F, Cl, Br, cyano, methoxy
- R 2 and R 2 ' are each independently H;
- R is H, unsubstituted or X-substituted straight or branched alkyl of 1-6 carbons;
- R 4 and R 5 are each independently H, unsubstituted or X-substituted straight or branched chain alkyl of 1-6 carbons, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, Sec-butyl, isobutyl, tert-butyl, n-pentyl, isopentyl, neopentyl, etc.
- R 4 and R 5 can optionally form a ring, such as a five-membered ring (such as cyclopentyl), a six-membered ring (eg cyclohexyl), seven-membered ring (eg cycloheptyl), etc.;
- Y is O
- X is F, Cl , Br, I, CN, NO2, NH2 , CF3 , SH, OH, OCH3 , OC2H5 , COOH , straight or branched chain alkyl of 1-6 carbons.
- halogen refers to fluorine, chlorine, bromine and iodine.
- C 1-4 alkyl refers to straight or branched chain alkyl groups having 1-4 carbon atoms, such as methyl, ethyl, n-propyl, isopropyl, n-butyl, isobutyl, tertiary Butyl.
- C 1-4 alkoxy refers to a straight or branched chain alkoxy having 1-4 carbon atoms, such as methoxy, ethoxy, n-propoxy, isopropoxy, n-butoxy base, isobutoxy, tert-butoxy.
- Aryl is eg phenyl, naphthyl, phenanthryl, anthracenyl and the like.
- Heteroaryl has 1, 2 or 3 heteroatoms selected from S, O, N, eg, pyridyl, pyrimidinyl, pyridazinyl, pyrazinyl, thienyl, furyl, pyrrolyl, pyridyl azolyl, imidazolyl, thiazolyl, azolyl, iso azolyl, indolyl, benzo[b]thienyl, benzo[b]furanyl, quinolinyl, isoquinolinyl, quinazolinyl and the like.
- the compounds of formula (I) and formula (II) are selected from the following compounds:
- salts such as salts formed by compounds of formula (I) or formula (II) with inorganic or organic acids, such as hydrochloric acid, sulfuric acid, phosphoric acid, hydrobromic acid, nitric acid, etc.
- Organic acids such as formic acid, acetic acid, propionic acid, valeric acid, diethylacetic acid, trifluoroacetic acid, maleic acid, malonic acid, succinic acid, pimelic acid, fumaric acid, lactic acid, tartaric acid, malic acid, citric acid , gluconic acid, ascorbic acid, niacin, isonicotinic acid, benzoic acid, methanesulfonic acid, ethanesulfonic acid, benzenesulfonic acid, toluenesulfonic acid, naphthalenedisulfonic acid, etc.
- the present invention provides the preparation method of the above-mentioned compound, comprising the following steps:
- R 3 ' is an organic group, preferably methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, benzyl, etc.; preferably, the organic solvent is selected from Dioxane, tetrahydrofuran, dichloromethane, 1,2-dichloroethane, chloroform, toluene, n-hexane, cyclohexane, tert-butyl methyl ether, pyridine and mixtures of two or more thereof, more preferably dichloromethane oxane, tetrahydrofuran or mixtures thereof;
- the organic solvent is selected from benzene, toluene, xylene, dioxane, DMF, DMSO, acetonitrile and mixtures of two or more thereof, more preferably dioxane, toluene, xylene and two or more thereof a mixture of one or more;
- the metal catalyst is selected from palladium carbon, Raney nickel, iron powder, zinc powder, and stannous chloride;
- the hydrogen source is selected from hydrogen, hydrazine hydrate, amine formate, formic acid, ammonium chloride, cyclohexene;
- the organic solvent is selected from methanol, ethanol, n-butanol, tert-butanol, tetrahydrofuran, dichloromethane, 1,2-dichloroethane, chloroform, toluene, n-hexane, cyclohexane , tert-butyl methyl ether and a mixture of two or more thereof, more preferably methanol, ethanol or a mixture thereof;
- the organic solvent is an inert solvent, more preferably an aprotic solvent , and further preferably the organic solvent is selected from acetonitrile, chloroform, dichloromethane, 1,2-dichloroethane, N,N-dimethylformamide, toluene, n-hexane, cyclohexane, tetrahydrofuran, tert-butyl methyl ether and Wherein the mixture of two or more, further preferably the organic solvent is selected from dichloromethane, 1,2-dichloroethane or, N,N-dimethylformamide and the mixture of two or more thereof; preferably , the condensation reagent is
- R 3 ' in the organic alcohol R 3 'OH is an organic group, further preferably, the organic alcohol R 3 'OH is selected from methanol, ethanol, propanol, isopropanol, n-butanol, isobutanol, tert-butanol, benzyl alcohol and mixtures of two or more thereof, further preferably methanol, ethanol, isopropanol, tert-butanol and mixtures of two or more thereof; Fluoroacetic acid, methanesulfonic acid and mixtures of two or more thereof; preferably, the inorganic acid is selected from hydrochloric acid, sulfuric acid and mixtures thereof.
- the present invention also provides a pharmaceutical composition
- a pharmaceutical composition comprising a compound of formula (I) or formula (II) or a pharmaceutically acceptable salt thereof, and a pharmaceutically acceptable excipient.
- the dosage forms of the pharmaceutical composition of the present invention include, but are not limited to, tablets, capsules, pills, suppositories, soft capsules, oral liquids, suspensions, injections and other commonly used pharmaceutical forms.
- the present invention provides a method for preventing and/or treating a disorder associated with abnormal glycogen metabolism, comprising administering to an individual in need thereof an effective amount of formula (I) or formula (II) ) compound or a pharmaceutically acceptable salt thereof.
- the dosage of a compound of formula (I) or formula (II), or a pharmaceutically acceptable salt thereof will vary from formulation to formulation.
- the total amount of the compound of formula (I) or formula (II) administered per kilogram per 24 hours is about 0.01-800 mg, preferably a total amount of 0.1-100 mg /kg. If necessary, it is administered in several single doses. However, it is also possible to deviate from the above-mentioned amounts if necessary, i.e. it depends on the type and weight of the subject to be treated, the behavior of the individual with the drug, the nature and severity of the disease, the type of formulation and administration, and the time of administration and interval.
- the present invention provides a compound of formula (I) or formula (II) of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present invention in the preparation for use in the treatment and/or prevention of and Use in medicine for disorders associated with abnormal glycogen metabolism.
- diseases related to abnormal glycogen metabolism include diabetes (especially type 2 diabetes) or its complications (such as diabetic nephropathy, diabetic foot, diabetic neuropathy, cardiovascular and cerebrovascular diseases complicated by diabetes, etc.), hyperlipidemia disease, obesity, ischemic cardiovascular and cerebrovascular diseases (especially myocardial infarction, angina pectoris, myocardial ischemia, myocardial ischemia-reperfusion, arrhythmia, coronary heart disease, cerebral ischemia, stroke, cerebral infarction or ischemic neurodegeneration disease, etc.), hyperinsulinemia, insulin resistance, fasting hyperglycemia, hypertension or its complications, atherosclerosis, metabolic syndrome or tumors.
- diabetes especially type 2 diabetes
- complications such as diabetic nephropathy, diabetic foot, diabetic neuropathy, cardiovascular and cerebrovascular diseases complicated by diabetes, etc.
- hyperlipidemia disease especially obesity, ischemic cardiovascular and cerebrovascular diseases (especially myocardial infarction, angina pectoris, myocardial ischemia, myo
- the present invention provides a compound of formula (I) or formula (II) of the present invention or a pharmaceutically acceptable salt thereof or a pharmaceutical composition of the present invention in the preparation of a glycogen phosphorylase inhibitor the use of.
- Figure 1 shows the preparation process of some compounds of the present invention.
- R 3 ' is an organic group, preferably methyl, ethyl, propyl, isopropyl, n-butyl, isobutyl, tert-butyl, benzyl and the like.
- Figure 2 is a mouse echocardiographic evaluation of the effect of compound treatment of Example 8 on myocardial ischemia-reperfusion injury
- (A) is a representative image of small animal M-mode ultrasound;
- (B) is a statistical map of small animal ultrasound EF, FS, EDV and ESV (*p ⁇ 0.05)
- 5-Chloroindole-2-carboxylic acid (0.29 g, 1.48 mmol) was dissolved in dry DMF (7.4 mL), and HATU (0.38 g, 1 mmol, 0.4 mol/L of dry DMF) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.14 g, 0.72 mmol) was dissolved in dry DMF (3.6 mL), and HATU (0.253 g, 0.665 mmol, 0.4 mol/L) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.302 g, 1.549 mmol) was dissolved in dry DMF (7.75 mL), and HATU (0.4 g, 1.052 mmol, 0.4 mol/L) was slowly added with stirring.
- 5-Chloroindole-2-carboxylic acid (0.131 g, 0.668 mmol) was dissolved in dry DMF (3.34 mL), and HATU (0.17 g, 0.447 mmol, 0.4 mol/L) was slowly added with stirring.
- 5-Chloroindole-2-carboxylic acid (0.255 g, 1.307 mmol) was dissolved in dry DMF (6.5 mL), and HATU (0.435 g, 1.144 mmol, 0.4 mol/L) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.1 g, 0.513 mmol) was dissolved in dry DMF (2.56 mL), and HATU (0.147 g, 0.387 mmol, 0.4 mol/L) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.063 g, 0.323 mmol) was dissolved in dry DMF (1.65 mL), and HATU (0.083 g, 0.218 mmol, 0.4 mol/L) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.067 g, 0.342 mmol) was dissolved in dry DMF (1.71 mL), and HATU (0.087 g, 0.2288 mmol, 0.4 mol/L) was slowly added under stirring.
- 5-Chloroindole-2-carboxylic acid (0.22 g, 1.12 mmol) was dissolved in dry DMF (5.6 mL), and HATU (0.394 g, 1.036 mmol, 0.4 mol/L) was slowly added under stirring.
- Preparation of reagents 1) Preparation of color developing solution: Weigh 5g of ammonium molybdate, dissolve it in 500ml of 1M HCl, stir with a stirrer, add 190mg of malachite green after it is completely dissolved, continue to stir until it is completely dissolved, and use tin foil Protect from light; 2) Preparation of buffer solution: 1 Precisely weigh Hepes 0.5958g, dissolve it in 5ml H 2 O, adjust the pH to 7.2 with 10M NaOH, and prepare Hepes with a final concentration of 0.5M; 2 Precisely weigh KCl 0.3728 g, dissolved in 5ml H 2 O to prepare KCl with a final concentration of 1M; 3Precisely weigh 0.0255g of MgCl 3 , dissolve in 1ml H 2 O, and prepare a final concentration of 125mM MgCl 2 ; 4Precisely weigh EGTA 0.0476g, dissolve in 5ml
- Determination of the dose-response curve of rabbit muscle glycogen phosphorylase activity by reading the OD value at 655nm after adding different concentrations of GPa to the chromogenic solution, the dose-response curve was measured.
- the amount of GPa can be selected as 250ng from the dose-response curve.
- test results show that most of the compounds in the examples have IC 50 ⁇ 1 ⁇ M, which are proved to be effective, as shown in Table 1 below.
- the pharmacological data show that the compound of the general formula (I) of the present invention has an inhibitory effect on glycogen phosphorylase, and the activity is similar to that of the known compound (the compound of Example 1 of CN103497181A).
- the compound of formula (I) of the present invention has the activity of inhibiting glycogen phosphorylase, so it can be used to treat various diseases related to abnormal glycogen metabolism.
- Plasma sample 0.2mL, add 0.4mL acetonitrile solution, vortex for 5min, centrifuge at 10000r ⁇ min -1 for 10min, take the supernatant, centrifuge at 10000r ⁇ min -1 for 10min, then take the supernatant, and use HPLC to determine the drug concentration in plasma .
- the pharmacokinetic parameters are listed in Table 2:
- the compound of the present invention has a longer half-life, higher Cmax and better bioavailability than the prior art compound (the compound in Example 1 of CN103497181A), thereby improving the curative effect.
- mice After 4-week-old male C57 BL/6J mice were adaptively fed for 5 days, 10 mice were randomly selected as normal control group, fed with low-fat diet, and the remaining mice were fed with high-fat diet. Mice were housed in a cage of 5 mice with free access to food and water, a light-dark cycle of 12 hours, and a room temperature of 22°C to 26°C. After the mice were continuously fed for 12 weeks, fasting and glucose tolerance were measured to evaluate insulin resistance, which showed that the modeling was successful.
- the high-fat feeding group was randomly divided into the following experimental groups according to 10 animals/group: model control group, metformin group (400 mg/kg, gavage) and Example 8 compound group (high, medium and low dose groups, respectively For 50, 25, 12.5 mg/kg, gavage, once a day).
- model control group metformin group (400 mg/kg, gavage)
- Example 8 compound group high, medium and low dose groups, respectively For 50, 25, 12.5 mg/kg, gavage, once a day.
- the patients were given continuous administration for 4 weeks, and they fasted overnight before the last administration.
- the blood glucose levels of the model control group on the 0, 7, 14, 21, and 27 days of administration were significantly higher than those of the normal control group ( ## p ⁇ 0.01).
- the metformin 400mg/kg group showed significant differences in blood glucose, which were lower than those in the model control group ( ** p ⁇ 0.01);
- the compound of Example 8 of the present invention 50mg/kg group showed significant differences on the 7th, 21st, and 27th days of administration.
- the blood glucose values on the 14th, 21st, and 27th days were significantly lower than those in the model control group ( * p ⁇ 0.05, ** p ⁇ 0.01), and the blood glucose values in the 25mg/kg and 12.5mg/kg groups were significantly lower on the 21st and 27th days of administration compared with the model control group ( ** p ⁇ 0.01).
- Table 3 The effect of the compound of Example 8 of the present invention on the blood glucose of the C57BL/6 hyperglycemia mouse model induced by high-fat diet
- mice 8-week-old SPF grade C57 BL/6J mice, weighing 20-25g, were randomly divided into the following experimental groups, 10 mice/group: sham operation group (Sham), I/R model group (I.R Model) and Example 8 Compound group high dose group (HD 100mg/kg), middle dose group (MD 50mg/kg) and low dose group (LD 30mg/kg).
- the mice were anesthetized with isoflurane, and after observing that they had no righting response, they were fixed in the supine position on the operation board.
- the surgical site on the front of the mouse chest was disinfected with 75% alcohol, and an incision of about 1 cm was cut along the third and fourth intercostal space.
- the pectoralis major and minor muscles were bluntly separated, and a curved hemostat was used to penetrate the intercostal muscle. Deep into the chest cavity, with its power, quickly squeeze the heart out of the intercostal space.
- the left anterior descending coronary artery was ligated with a suture needle, causing myocardial ischemia in the mouse, and the anterior wall of the left ventricle was observed to turn pale.
- the heart was quickly returned to the thoracic cavity for repositioning, the end of the ligation slip-knot was exposed outside the body, and the skin incision was sutured with a suture needle. The timing of the ligation was started.
- the ligature was gently pulled by hand to loosen the knot to restore blood supply to the heart.
- the mice were placed on a 37°C insulation pad until they recovered their automatic crawling ability.
- the I/R model was established 24 hours after the blood supply to the heart was restored.
- the high, medium and low dose groups of the compound of Example 8 were administered by tail vein injection after I/R modeling, once a day, for 7 consecutive days.
- EF ejection fraction
- FS short-axis shortening
- EDV end-diastolic volume
- ESV end-systolic volume
- LVEF left ventricular ejection fraction (Left Ventricular Ejection Fractions), refers to: the percentage of stroke volume in ventricular end-diastolic volume.
- the ventricular diastolic volume is about 125mL for the left ventricle, about 137mL for the right ventricle, and the stroke volume is 60-80mL, that is, ejection of blood.
- the percentage of the stroke volume in the diastolic volume of the ventricle is called the ejection fraction.
- the ejection fraction of the human body is about 55% to 65% at rest.
- the ejection fraction is related to the contractility of the myocardium. The stronger the myocardial contractility, the greater the stroke volume and the greater the ejection fraction.
- the left ventricular ejection fraction is ⁇ 50%; the right ventricular ejection fraction is ⁇ 40%. If it is less than this value, it means cardiac insufficiency.
- LVFS Left Ventricular Fractional shortening (Left Ventricular Fractional shortening), refers to: the left ventricular end-diastolic diameter minus the left ventricular end-systolic diameter, the percentage of the left ventricular end-diastolic diameter, this value reflects the contraction of the heart and diastolic function.
- LVEDV Left Ventricular End-diastolic volume, literally, refers to the volume within the left ventricle at end-diastolic, used to calculate LVEF and LVFS.
- LVESV Left Ventricular End-systolic volume, literally, refers to the volume in the ventricle at the end of systolic left ventricle, used to calculate LVEF and LVFS.
Landscapes
- Health & Medical Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Public Health (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Life Sciences & Earth Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Engineering & Computer Science (AREA)
- Diabetes (AREA)
- Epidemiology (AREA)
- Biomedical Technology (AREA)
- Endocrinology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- Heart & Thoracic Surgery (AREA)
- Cardiology (AREA)
- Psychiatry (AREA)
- Urology & Nephrology (AREA)
- Hospice & Palliative Care (AREA)
- Emergency Medicine (AREA)
- Hematology (AREA)
- Obesity (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
Abstract
涉及作为糖原磷酸化酶抑制剂的式(I)苯并嗪-4-酮化合物、其制备方法及其用于治疗和/或预防与糖原代谢异常相关的疾病的药物中的用途。
Description
本发明涉及药物化学领域,具体涉及作为糖原磷酸化酶抑制剂的苯并嗪-4-酮化合物、其制备方法及医药用途。
肝脏是禁食状态下调节血糖的重要器官。据估算,在禁食过夜之后,74%的空腹血糖来源于肝脏的糖原分解,其余的来源于肝脏的糖异生。在2型糖尿病患者中,肝脏葡萄糖的生成速率显著增加,肝脏葡萄糖产生偏高。因此,抑制肝脏葡萄糖生成已成为研制新型抗糖尿病药物的重要靶标之一。
目前在临床上,二甲双胍这一临床上首选的降糖药,被认为主要是通过抑制肝脏糖异生作用来降低血糖;而在糖原降解领域,尚无有效的作用药物。而对于那些空腹血糖>14mg/dl(7.8mM)的2型糖尿病患者,抑制肝脏糖原降解,从而降低其肝糖输出,有助于降低其空腹血糖。
糖原磷酸化酶(glycogen phosphorylase)是催化糖原降解(glycogenolysis)的关键酶,该酶催化糖原的磷酸解,产生的葡萄糖-1-磷酸在磷酸葡萄糖变位酶的催化下转变成葡萄糖-6-磷酸,后者在葡萄糖-6-磷酸酶催化下生成葡萄糖,血糖升高。仍然需要能够抑制糖原磷酸化酶,从而抑制肝脏糖原降解的药物。
发明内容
本发明提供了一种具有糖原磷酸化酶抑制活性的式(I)所示苯并嗪酮化合物、其制备方法及医药用途。本发明的式(I)化合物因为能够抑制糖原磷酸化酶,从而可用于预防和/或治疗与糖原代谢异常相关的疾病。特别是,本发明的化合物在体内的半衰期长,生物利用度高,提高了疗效。
根据本发明的一个方面,本发明涉及如下式(I)化合物或其药学上可接受的盐:
其中:
X
1、X
2、X
3和X
4全为C或者X
1、X
2、X
3和X
4之一为N而其他的必须为C;
R
1和R
1’各自独立为H、卤素、羟基、氰基、C
1-4烷基、C
1-4烷氧基、氟代甲基、二氟甲基、三氟甲基、乙烯基、乙炔基;
R
2和R
2’各自独立为H、卤素、羟基、氰基、C
1-4烷基、C
1-4烷氧基、氟代甲基、二氟甲基、三氟甲基、乙烯基、乙炔基;
R
3为H、1-20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基、非取代或X取代的芳基、非取代或X取代的杂芳基;
R
4和R
5各自独立为H、1-20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基,R
4和R
5任选可以成环;
Y为CHR
6、NH、O、S;
R
6为H、1~20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基、苯基、苄基、萘基、腈基;
X为F、Cl、Br、I、CN、NO
2、NH
2、CF
3、SH、OH、OCH
3、OC
2H
5、COOH、1-10个碳的直链或支链烷基、2-10个碳的直链或支链烯烃基、2-10个碳的直链或支链炔烃基、芳基、杂芳基。
优选地,式(I)化合物结构如下式(II)所示:
进一步优选,式(I)和式(II)化合物中:
X
1、X
2、X
3和X
4全为C或者X
2、X
3之一为N而其他的必须为C;
R
1和R
1’各自独立为H、卤素、氰基、C
1-4烷氧基;
R
2和R
2’各自独立为H;
R
3为H、1-20个碳的非取代的或X取代的直链或支链烷基、非取代或X取代的C
6-14芳 基、非取代或X取代的C
5-10杂芳基;
R
4和R
5各自独立为H、1-20个碳的非取代的或X取代的直链或支链烷基,R
4和R
5任选可以成环;
Y为CH
2、NH、O;
X为F、Cl、Br、I、CN、NO
2、NH
2、CF
3、SH、OH、OCH
3、OC
2H
5、COOH、1-10个碳的直链或支链烷基、2-10个碳的直链或支链烯烃基、2-10个碳的直链或支链炔烃基、C
6-14芳基、C
5-10杂芳基。
进一步优选,式(I)和式(II)化合物中:
X
1、X
2、X
3和X
4全为C或者X
2、X
3之一为N而其他的必须为C;
R
1和R
1’各自独立为H、F、Cl、Br、氰基、甲氧基;
R
2和R
2’各自独立为H;
R
3为H、1-6个碳的非取代的或X取代的直链或支链烷基;
R
4和R
5各自独立为H、1-6个碳的非取代的或X取代的直链或支链烷基,例如甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基等,R
4和R
5任选可以成环,例如五元环(例如环戊基)、六元环(例如环己基)、七元环(例如环庚基)等;
Y为O;
X为F、Cl、Br、I、CN、NO
2、NH
2、CF
3、SH、OH、OCH
3、OC
2H
5、COOH、1-6个碳的直链或支链烷基。
在本发明中,“卤素”是指氟、氯、溴和碘。“C
1-4烷基”是指具有1-4个碳原子的直链或支链烷基,例如甲基、乙基、正丙基、异丙基、正丁基、异丁基、叔丁基。“C
1-4烷氧基”是指具有1-4个碳原子的直链或支链烷氧基,例如甲氧基、乙氧基、正丙氧基、异丙氧基、正丁氧基、异丁氧基、叔丁氧基。“芳基”例如苯基、萘基、菲基、蒽基等。“杂芳基”具有1个、2个或3个选自S、O、N的杂原子,例如吡啶基、嘧啶基、哒嗪基、吡嗪基、噻吩基、呋喃基、吡咯基、吡唑基、咪唑基、噻唑基、
唑基、异
唑基、吲哚基、苯并[b]噻吩基、苯并[b]呋喃基、喹啉基、异喹啉基、喹唑啉基等。
进一步优选,式(I)和式(II)化合物选自如下化合物:
本领域技术人员可以理解,药学上可接受的盐例如式(I)或式(II)化合物与无机酸或有机酸形成的盐,无机酸例如盐酸、硫酸、磷酸、氢溴酸、硝酸等,有机酸例如甲酸、乙酸、丙酸、戊酸、二乙基乙酸、三氟乙酸、马来酸、丙二酸、琥珀酸、庚二酸、富马酸、乳酸、酒石酸、苹果酸、柠檬酸、葡糖酸、抗坏血酸、烟酸、异烟酸、苯甲酸、甲磺酸、乙磺酸、苯磺酸、甲苯磺酸、萘二磺酸等。
根据本发明的第二个方面,本发明提供了上述化合物的制备方法,包括如下步骤:
a)将
溶于氨水中或者溶于有机溶剂中并加入氨水,优选在惰性气体进一步优选氮气保护下,反应1-72小时,优选24-48小时,温度为0℃至回流,得
其中,R
3’为有机基团,优选甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、苯甲基等;优选地,所述有机溶剂选自二氧六环、四氢呋喃、二氯甲烷、1,2-二氯乙烷、氯仿、甲苯、正己烷、环己烷、叔丁基甲基醚、吡啶和其中两种或多种的混合物, 进一步优选二氧六环、四氢呋喃或其混合物;
b)将
溶于有机溶剂中,加入
和催化剂PPTS,优选在惰性气体进一步优选氮气保护下,反应1-72小时,温度为0℃至回流,得
优选地,所述有机溶剂选自苯、甲苯、二甲苯、二氧六环、DMF、DMSO、乙腈和其中两种或多种的混合物,进一步优选二氧六环、甲苯、二甲苯和其中两种或多种的混合物;
c)将
溶于有机溶剂中,加入氢源,采用金属催化剂催化还原苯环上的硝基,温度为0℃至回流,得
优选地,所述金属催化剂选自钯碳、雷尼镍、铁粉、锌粉,氯化亚锡;优选地,所述氢源选自氢气、水合肼、甲酸胺、甲酸、氯化铵、环己烯;优选地,所述有机溶剂选自甲醇、乙醇、正丁醇、叔丁醇、四氢呋喃、二氯甲烷、1,2-二氯乙烷、氯仿、甲苯、正己烷、环己烷、叔丁基甲基醚和其中两种或多种的混合物,进一步优选甲醇、乙醇或其混合物;
d)将取代的吲哚羧酸或吡咯并吡啶-2-羧酸
与
溶于有机溶剂中,加入缩合试剂与有机胺或无机碱,反应1-72小时,温度为0℃至45℃,即得;优选地,所述有机溶剂为惰性溶剂,进一步优选非质子性溶剂,进一步优选有机溶剂选自乙腈、氯仿、二氯甲烷、1,2-二氯乙烷、N,N-二甲基甲酰胺、甲苯、正己烷、环己烷、四氢呋喃、叔丁基甲基醚和其中两种或多种的混合物,进一步优选有机溶剂选自二氯甲烷、1,2-二氯乙烷或、N,N-二甲基甲酰胺和其中两种或多种的混合物;优选地,所述缩合试剂为酰胺化缩合试剂,进一步优选1-乙基-3-(3-二甲胺丙基)碳二亚胺盐酸盐(EDCI)、N,N′-二环己基碳二亚胺(DCC)、O-苯并三氮唑-N,N,N′,N′-四甲基脲四氟硼酸(TBTU)、2-(7-偶氮苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯(HATU)、1-丙基磷酸三环 酸酐(T
3P);优选地,所述无机碱选自碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾和其中两种或多种的混合物;优选地,所述有机胺为N,N-二异丙基乙胺、三乙胺或其混合物。
优选地,进一步包括如下步骤:
将β-羟基酸
溶于有机醇R
3’OH中,加入有机酸或无机酸作为催化剂,优选在惰性气体进一步优选氮气保护下,反应1-72小时,优选24-48小时,温度为0℃至回流,得
优选地,所述有机醇R
3’OH中R
3’为有机基团,进一步优选,有机醇R
3’OH选自甲醇、乙醇、丙醇、异丙醇、正丁醇、异丁醇、叔丁醇、苯甲醇和其中两种或多种的混合物,进一步优选甲醇、乙醇、异丙醇、叔丁醇和其中两种或多种的混合物;优选地,所述有机酸选自乙酸、三氟乙酸、甲磺酸和其中两种或多种的混合物;优选地,所述无机酸选自盐酸、硫酸和其混合物。
根据本发明的第三个方面,本发明还提供一种药物组合物,含有式(I)或式(II)化合物或其药学上可接受的盐,以及药学上可接受的辅料。
本领域技术人员可以理解,本领域各种常用的辅料均可用于本发明,包括但不限于填充剂、稀释剂、崩解剂、润滑剂、粘合剂、分散剂、润湿剂、溶剂、pH调节剂、矫味剂、防腐剂、抗氧化剂等等。
本发明药物组合物的剂型包括但不限于片剂、胶囊、丸剂、栓剂、软胶囊、口服液、混悬剂、注射液等药学上常用的剂型。
本领域技术人员可以理解,本发明药物组合物的各种剂型可以按照本领域中熟知的方法进行制备。
根据本发明的第四个方面,本发明提供了一种用于预防和/或治疗与糖原代谢异常相关的疾病的方法,包括给予有需要的个体有效量的式(I)或式(II)化合物或其药学上可接受的盐。
本领域技术人员可以理解,式(I)或式(II)化合物或其药学上可接受的盐的剂量将因配方而异。一般地,已证明有利的量,为达到所需结果,每千克每24小时给药的式(I)或式(II)化合物的总量为约0.01-800mg,优选的总量为0.1-100mg/kg。如果必要,以几次单剂量的形式给药。然而,如果必要,也可以偏离上述用量,即这取决于待治疗的受试者的类型和体重、个体对药物的行为、疾病的性质和严重性、制剂和给药的类型、以及给药时间和间隔。
根据本发明的第五个方面,本发明提供本发明的式(I)或式(II)化合物或其药学上可接受的盐或本发明的药物组合物在制备用于治疗和/或预防与糖原代谢异常相关的疾病的药 物中的用途。
根据本发明,与糖原代谢异常相关的疾病包括糖尿病(特别是2型糖尿病)或其并发症(例如糖尿病肾病、糖尿病足、糖尿病神经病变、糖尿病并发的心脑血管疾病等)、高脂血症、肥胖、缺血性心脑血管疾病(特别是心肌梗死、心绞痛、心肌缺血、心肌缺血再灌注、心律失常、冠心病、脑缺血、中风、脑梗死或缺血性神经退行性疾病等)、高胰岛素血症、胰岛素抵抗、禁食高血糖症、高血压或其并发症、动脉粥样硬化、代谢综合征或肿瘤。
根据本发明的第六个方面,本发明提供本发明的式(I)或式(II)化合物或其药学上可接受的盐或本发明的药物组合物在制备糖原磷酸化酶抑制剂中的用途。
图1为本发明部分化合物的制备过程。
在图1中,X
1、X
2、X
3、X
4、R
1、R
1’、R
2、R
2’、R
3、R
4、R
5、R
6、X和Y的定义如上述式(I)中所定义,R
3’为有机基团,优选甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、苯甲基等。
图2为小鼠心动超声评估实施例8化合物处理对心肌缺血再灌注损伤的影响
在图2中,(A)为小动物M型超声代表图;(B)为小动物超声EF,FS,EDV和ESV统计图(*p<0.05)
下面结合具体实施例,进一步阐述本发明。应理解,这些实施例仅用于说明本发明而不用于限制本发明的范围。此外,应理解,在阅读了本发明所记载的内容之后,本领域技术人员可以对本发明作各种改动或修改,这些等价形式同样落于本发明所限定的范围。
实施例1
2-羟基-5-硝基苯甲酸甲酯
将5-硝基水杨酸(4.0g,21.84mmol)溶于甲醇(70mL)中,搅拌情况下逐滴加入浓硫酸(1.5mL),滴加完成之后氮气保护反应体系。加热回流反应2天。反应结束后,将反应液中的甲醇除去后,加入K
2CO
3至不再有气泡产生,加入纯水(20mL),用乙酸乙酯萃取(3×50mL),合并有机层无水硫酸钠干燥2-3小时,过滤浓缩,硅胶柱层析(石油醚/乙酸乙酯=15%-20%),得白色固体(4.0g,93%)。m.p.112-114℃。
ESI-MS m/z:239.2(M+H)
+.
1H-NMR(400MHz,CDCl
3):4.04(s,3H),7.09(d,J=8.0Hz,1H),8.34(dd,J=8.0,4.0 Hz,1H),8.80(d,J=2.8Hz,1H),11.43(s,1H).
13C-NMR(100MHz,CDCl
3):169.3,166.2,140.0,130.6,126.7,118.7,112.1,53.1.
2-羟基-5-硝基苯甲酰胺
向氨水(70mL)溶液中加入5-硝基水杨酸甲酯(4.0g,20.29mmol),氮气保护反应体系,加热至50℃搅拌反应2天。反应结束后减压蒸干反应液,向残留物中加入纯水(30mL),并用2mol/L盐酸溶液调至近酸性。乙酸乙酯萃取(3×50mL),合并有机层无水硫酸钠干燥2-3小时,过滤浓缩,硅胶柱层析(石油醚/乙酸乙酯=30%-50%),得淡黄色固体(2.70g,73%)。m.p.130-132℃。
ESI-MS m/z:180.7(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):7.10(d,J=8.0Hz,1H),8.29(dd,J=8.0,4.0Hz,2H),8.81(s,1H),8.90(d,J=2.4Hz,1H),14.16(s,1H).
13C-NMR(100MHz,d6-DMSO):170.6,166.8,139.5,129.6,125.5,119.0,115.1.
2-甲基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.1g,0.549mmol)溶于甲苯(6mL)和乙醛(8mL)中,加入PPTS(0.14g,0.557mmol),N
2保护反应体系,80℃搅拌反应16h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=91/9-2/1),得浅黄色固体(0.0815g,71.37%)。m.p.216-218℃。
ESI-MS m/z:208.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.73(d,J=5.6Hz,3H),5.53-5.57(m,1H),7.03(s,1H),7.11(d,J=8.8Hz,1H),8.35(dd,J=9.2,2.8Hz,1H),8.65(d,J=2.8Hz,1H).
13C-NMR(100MHz,CDCl
3):162.2,162.0,136.1,129.6,124.7,118.1,117.9,82.0,20.2.
2-甲基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2-甲基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.2874g,1.382mmol)(粗产品)溶于无水乙醇(30mL),加入HCOONH
4(0.74g,11.7mmol)、Pd/C(0.051g,0.4806mmol),室温搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=3/1-1/1),得浅黄色固体(0.2262g,91.95%)。m.p.180-182℃。
ESI-MS m/z:179.0(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.61(d,J=6.0Hz,3H),3.61(s,2H),5.33-5.38(m,1H),6.33(s,1H),6.81(s,2H),7.22(t,J=0.8Hz,1H).
13C-NMR(100MHz,CDCl
3):164.1,150.8,141.5,121.9,118.5,117.3,113.1,80.8,20.3.
N-(2-甲基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.29g,1.48mmol)溶于干燥DMF(7.4mL)中,在搅拌的情况下分别缓慢加入HATU(0.38g,1mmol,0.4mol/L的干燥DMF溶液)、三乙胺(3mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2-甲基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.1762g,0.9899mmol,5mL约0.2mol/L的干燥DMF溶液),45℃下搅拌4.5h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得浅绿色固体(0.1786g,50.68%)。m.p.302-304℃。
ESI-MS m/z:354.1(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):1.99(s,3H),5.42(d,J=4.4Hz,1H),7.06(d,J=8.4Hz,1H),7.23(d,J=7.2Hz,1H),7.41(s,1H),7.48(d,J=8Hz,1H),7.78(s,1H),7.94(d,J=7.6Hz,1H),8.23(s,1H),8.70(s,1H),10.38(s,1H),11.95(s,1H).
13C-NMR(100MHz,d
6-DMSO):163.1,159.7,154.1,135.7,133.8,133.3,128.5,126.8,124.9,124.3,121.3,119.3,118.8,117.1,114.5,103.8,81.6,20.2.
实施例2
2-乙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.6g,3.29mmol)溶于甲苯(10mL)和丙醛(10mL)中,加入PPTS(0.83g,3.3mmol),N
2保护反应体系,80℃搅拌反应13h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=22/3-3/1),得白色固体(0.4903g,67.13%)。m.p.205-207℃。
ESI-MS m/z:222.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.20(t,J=7.6Hz,3H),2.02-2.11(m,2H),5.40(t,J=5.2Hz,1H),7.14(d,J=8.8Hz,1H),8.17(s,1H),8.36(dd,J=9.2,2Hz,1H),8.84(d,J=2Hz,1H).
13C-NMR(100MHz,CDCl
3):162.7,162.4,142.7,129.5,124.6,118.2,117.9,86.1,27.0,7.7.
2-乙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2-乙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.554g,2.485mmol)溶于70mL无水乙醇,加入HCOONH
4(1.28g,20.298mmol)、Pd/C(0.079g,0.745mmol),室温下搅拌,TLC监测反应,3h后反应结束,乙醇/石油醚重结晶,得白色固体(0.1478g,30.98%)。m.p.128-131℃。
ESI-MS m/z:193.0(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.12(t,J=7.6Hz,3H),1.85-2.01(m,2H),3.59(br s,1H),5.17(t,J=5.2Hz,1H),6.82(d,J=7.2Hz,1H),6.83(s,2H),7.24(s,1H).
13C-NMR(100MHz,CDCl
3):164.4,150.8,141.2,121.9,118.6,117.3,113.1,84.9,27.1,8.0.
N-(2-乙基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.14g,0.72mmol)溶于干燥DMF(3.6mL)中,在搅拌的情况下分别缓慢加入HATU(0.253g,0.665mmol,0.4mol/L的干燥DMF溶液)、三乙胺(2.009mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2-乙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.1277g,0.665mmol,3.33mL约0.2mol/L的干燥DMF溶液),45℃下搅拌22h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得浅黄色固体(0.0989g,40.30%)。m.p.308-310℃。
ESI-MS m/z:367.9(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):1.04(t,J=5.6Hz,3H),1.76-1.92(m,2H),5.20-5.30(m,1H),7.07(d,J=8.4Hz,1H),7.24(d,J=8Hz,1H),7.42(s,1H),7.49(d,J=8.4Hz,1H),7.79(s,1H),7.95(d,J=8Hz,1H),8.23(s,1H),8.70(s,1H),10.39(s,1H),11.96(s,1H).
13C-NMR(100MHz,d
6-DMSO):163.1,159.7,154.0,135.7,133.7,133.3,128.5,126.8,124.9,124.3,121.3,119.3,118.9,117.2,114.5,103.8,85.4,26.7,8.3.
实施例3
2-丙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.6g,3.29mmol)溶于甲苯(10mL)和丁醛(10mL)中,加入PPTS(0.83g, 3.3mmol),N
2保护反应体系,80℃搅拌反应20.5h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=47/3-1/1),得白色固体(0.4417g,56.89%)。m.p.191-193℃。
ESI-MS m/z:236.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.06(t,J=7.4Hz,3H),1.58-1.70(m,2H),1.89-2.08(m,2H),5.42(t,J=4.8Hz,1H),7.11(d,J=9.0Hz,1H),7.46(s,1H),8.34(dd,J=9.0,2.8Hz,1H),8.84(d,J=2.8Hz,1H).
13C-NMR(100MHz,CDCl
3):162.3,142.8,129.5,124.7,118.2,117.9,85.0,35.8,16.9,13.7.
2-丙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2-丙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.397g,1.682mmol)溶于无水乙醇(70mL)中,加入HCOONH
4(0.85g,13.48mmol)、Pd/C(0.053g,0.5mmol),室温下搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=4/1-7/3),得白色固体(0.2638g,76.13%)。m.p.114-116℃。
ESI-MS m/z:207.0(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.01(t,J=7.4Hz,3H),1.50-1.65(m,2H),1.76-1.98(m,2H),3.61(br s,2H),5.20(t,J=4.9Hz,1H),6.80(s,2H),7.04(s,1H),7.23(s,1H).
13C-NMR(100MHz,CDCl
3):164.5,150.9,141.3,121.9,118.7,117.3,113.1,83.9,35.9,17.1,13.8.
N-(2-丙基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.302g,1.549mmol)溶于干燥的DMF(7.75mL)中,在搅拌的情况下分别缓慢加入HATU(0.4g,1.052mmol,0.4mol/L的干燥DMF溶液)、三乙胺(3.16mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2-丙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.2126g,1.032mmol,5.16mL约0.2mol/L的干燥DMF溶液),45℃下搅拌25h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得灰白色固体(0.1561g,39.49%)。m.p.301-303℃。
ESI-MS m/z:382.0(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):0.95(t,J=7.4Hz,3H),1.49-1.57(m,2H),1.77-1.82(m,2H),5.29(t,J=4.9Hz,1H),7.06(d,J=8.8Hz,1H),7.23(dd,J=8.7,2.0Hz,1H),7.42(d,J=1.5Hz,1H),7.49(d,J=8.7Hz,1H),7.78(d,J=1.8Hz,1H),7.94(dd,J=8.9,2.6Hz,1H),8.22(d,J=2.6Hz,1H),8.68(s,1H),10.37(s,1H),11.94(s,1H).
13C-NMR(100MHz,d
6-DMSO): 163.0,159.7,154.0,135.7,133.7,133.3,128.6,126.8,124.9,124.3,121.3,119.3,118.9,117.1,114.5,103.8,84.5,35.6,17.0,14.1.
实施例4
2-丁基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.6g,3.29mmol)溶于甲苯(10mL)和正戊醛(10mL)中,加入PPTS(0.83g,3.3mmol),N
2保护反应体系,80℃搅拌反应16h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=47/3-7/3),得白色固体(0.5885g,71.55%)。m.p.178-180℃。
ESI-MS m/z:250.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.99(t,J=7.2Hz,3H),1.44-1.62(m,4H),1.92-2.10(m,2H),5.41(t,J=5.1Hz,1H),7.11(d,J=9.0Hz,1H),7.86(s,1H),8.34(dd,J=9.0,2.8Hz,1H),8.83(d,J=2.7Hz,1H).
13C-NMR(100MHz,CDCl
3):162.5,162.3,142.8,129.5,124.6,118.2,117.9,85.3,33.5,25.5,22.3,13.9.
2-丁基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2-丁基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.419g,1.676mmol)溶于无水乙醇(50mL)中,加入HCOONH
4(0.85g,13.48mmol)、Pd/C(0.053g,0.5mmol),室温下搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=17/3-2/1),得灰白色固体(0.1512g,41.01%)。HPLC analysis:87.5%.m.p.128-130℃。
ESI-MS m/z:220.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.95(t,J=7.2Hz,3H),1.38-1.35(m,4H),1.78-1.99(m,2H),3.60(br s,2H),5.19(t,J=4.9Hz,1H),6.80(s,2H),6.89(s,1H),7.22(s,1H).
13C-NMR(100MHz,CDCl
3):164.4,150.9,141.4,121.9,118.7,117.3,113.1,84.1,33.6,25.8,22.4,13.9.
N-(2-丁基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.131g,0.668mmol)溶于干燥的DMF(3.34mL)中,在搅拌的情况下分 别缓慢加入HATU(0.17g,0.447mmol,0.4mol/L的干燥DMF溶液)、三乙胺(1.36mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2-丁基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.098g,0.445mmol,2.23mL约0.2mol/L的干燥DMF溶液),45℃下搅拌24h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得灰白色固体(0.0556g,31.47%)。m.p.299-301℃。
ESI-MS m/z:396.0(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):0.91(t,J=7.3Hz,3H),1.33-1.50(m,4H),1.78-1.82(m,2H),5.28(t,J=5.2Hz,1H),7.06(d,J=8.8Hz,1H),7.23(dd,J=8.7,2.0Hz,1H),7.41(d,J=1.4Hz,1H),7.48(d,J=8.7Hz,1H),7.78(d,J=1.8Hz,1H),7.94(dd,J=8.9,2.6Hz,1H),8.22(d,J=2.6Hz,1H),8.66(s,1H),10.36(s,1H),11.93(s,1H).
13C-NMR(100MHz,d
6-DMSO):163.0,159.7,154.0,135.7,133.7,133.3,128.6,126.8,124.9,124.3,121.3,119.3,118.9,117.1,114.5,103.8,84.7,33.3,25.7,22.3,14.3.
实施例5
2-戊基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.5g,2.747mmol)溶于甲苯(10mL)和正己醛(10mL)中,加入PPTS(0.69g,2.745mmol),N
2保护反应体系,80℃搅拌反应16h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=100/0-2/1),得白色固体(0.4874g,67.21%)。m.p.174-176℃。
ESI-MS m/z:264.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.95(t,J=6.9Hz,3H),1.40-1.42(m,4H),1.58-1.63(m,2H),1.91-2.09(m,2H),5.41(t,J=5.3Hz,1H),7.11(d,J=9.0Hz,1H),7.93(s,1H),8.34(dd,J=9.0,2.7Hz,1H),8.82(d,J=2.7Hz,1H).
13C-NMR(100MHz,CDCl
3):162.6,162.3,142.8,129.5,124.6,118.2,117.9,85.3,33.8,31.3,23.1,22.4,13.9.
2-戊基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2-戊基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.44g,1.67mmol)溶于无水乙醇(50mL),加入HCOONH
4(0.841g,13.34mmol)、Pd/C(0.053g,0.5mmol),室温下搅拌反应3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=17/3-2/1),得白色固体(0.2727g,69.78%)。m.p.139-141℃。
ESI-MS m/z:234.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.92(t,J=6.7Hz,3H),1.35-1.36(m,4H),1.49-1.57(m,2H),1.77-1.98(m,2H),3.61(br s,2H),5.19(t,J=5.1Hz,1H),6.80(s,2H),6.90(s,1H),7.22(s,1H).
13C-NMR(100MHz,CDCl
3):164.4,150.9,141.4,121.9,118.7,117.3,113.1,84.1,33.9,31.4,23.4,22.5,13.9.
N-(2-戊基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.189g,0.964mmol)溶于干燥的DMF(4.82mL)中,在搅拌的情况下分别缓慢加入HATU(0.245g,0.644mmol,0.4mol/L的干燥DMF溶液)、三乙胺(1.937mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2-戊基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.1505g,0.643mmol,3.3mL约0.2mol/L的干燥DMF溶液),45℃下搅拌23.5h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得白色固体(0.2257g,85.40%)。
ESI-MS m/z:409.9(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):0.89(t,J=6.8Hz,3H),1.29-1.33(m,4H),1.46-1.55(m,2H),1.77-1.81(m,2H),5.28(t,J=4.8Hz,1H),7.05(d,J=8.8Hz,1H),7.22(dd,J=8.7,2.1Hz,1H),7.45(d,J=1.5Hz,1H),7.48(d,J=8.8Hz,1H),7.76(d,J=1.9Hz,1H),7.98(dd,J=8.9,2.7Hz,1H),8.26(d,J=2.6Hz,1H),8.67(s,1H),10.56(s,1H),12.09(s,1H).
13C-NMR(100MHz,d
6-DMSO):163.0,159.6,153.9,135.6,133.8,133.4,128.5,126.8,124.8,124.3,121.2,119.3,118.9,117.1,114.4,104.3,84.7,33.5,31.4,23.2,22.4,14.3.
实施例6
2,2-二甲基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.8g,4.395mmol)溶于甲苯(10mL)和丙酮(18mL)中,加入PPTS(1.1g,4.377mmol),N
2保护反应体系,80℃搅拌反应53h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=4/1-1/1),得白色固体(0.3293g,32.3%)。m.p.199-201℃。
ESI-MS m/z:222.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.74(s,6H),7.06(d,J=8.8Hz,1H),8.34(d,J=9.2Hz,2H),8.83(s,1H).
13C-NMR(100MHz,CDCl
3):161.3,160.7,142.4,129.7,124.3,118.3,116.8,89.3,27.9.
2,2-二甲基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2,2-二甲基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.3293g,1.483mmol)溶于无水乙醇(40mL)中,加入HCOONH
4(0.749g,11.87mmol)、Pd/C(0.047g,0.445mmol),室温搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=2/1),得紫褐色固体(0.2175g,76.54%)。m.p.148-150℃。
ESI-MS m/z:192.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.62(s,6H),3.58(s,2H),6.74(d,J=8.4Hz,1H),6.81(dd,J=8.4,2.4Hz,1H),7.23(d,J=2.4Hz,1H),7.32(s,1H).
13C-NMR(100MHz,CDCl
3):163.1,148.7,140.9,122.0,117.8,117.4,113.0,87.0,27.5.
N-(2,2-二甲基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.255g,1.307mmol)溶于干燥的DMF(6.5mL)中,在搅拌的情况下分别缓慢加入HATU(0.435g,1.144mmol,0.4mol/L的干燥DMF溶液)、三乙胺(3.432mmol,2mol/L的干燥DMF溶液),室温搅拌10min后,加入2,2-二甲基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.2196g,1.144mmol,5.65mL约0.2mol/L的干燥DMF溶液),45℃下搅拌3h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=4/1-1/1),得灰白色固体(0.0406g,9.59%)。m.p.314-316℃。
ESI-MS m/z:368.0(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):1.54(s,6H),7.00(d,J=8.8Hz,1H),7.22(d,J=8.8Hz,1H),7.40(s,1H),7.43(d,J=8.8Hz,1H),7.78(s,1H),7.93(dd,J=8.8,2.4Hz,1H),8.21(d,J=2Hz,1H),8.67(s,1H),10.36(s,1H),11.94(s,1H).
13C-NMR(100MHz,d
6-DMSO):161.5,159.7,151.9,135.7,133.4,133.3,128.5,127.0,124.9,124.3,121.3,118.9,117.6,117.5,114.5,103.8,87.9,27.7.
实施例7
2,2-二乙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.55g,3.022mmol)溶于甲苯(10mL)和3-戊酮(7mL)中,加入PPTS(0.87g,3.466mmol),N
2保护反应体系,80℃搅拌反应48h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=91/9-4/1),得浅绿色固体(0.113g,14.96%)。m.p.176-178℃。
ESI-MS m/z:250.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.03(t,J=7.6Hz,6H),1.91-2.02(m,4H),7.06(d,J=9.2Hz,1H),8.28(s,1H),8.33(dd,J=8.8,2.8Hz,1H),8.81(d,J=2.8Hz,1H).
13C-NMR(100MHz,CDCl
3):161.5,161.0,142.2,129.7,124.2,118.0,116.8,94.0,31.0,7.6.
2,2-二乙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将2,2-二乙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.2347g,0.9388mmol)溶于无水乙醇(50mL)中,加入HCOONH4(0.593g,9.4mmol)、Pd/C(0.03g,0.28mmol),室温搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=2/1),得灰色固体(0.138g,66.82%)。m.p.187-189℃。
ESI-MS m/z:220.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.96(t,J=7.6Hz,6H),1.83-1.89(m,4H),3.58(br s,2H),6.75(d,J=8.8Hz,1H),6.82(dd,J=8.4,2.8Hz,1H),6.90(s,1H),7.23(d,J=2.4Hz,1H).
13C-NMR(100MHz,CDCl
3):163.1,148.8,140.5,122.1,117.7,117.5,113.1,91.4,30.2,7.7.
N-(2,2-二乙基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.1g,0.513mmol)溶于干燥DMF(2.56mL)中,在搅拌的情况下分别缓慢加入HATU(0.147g,0.387mmol,0.4mol/L的干燥DMF溶液)、三乙胺(1.148mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2,2-二乙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.085g,0.386mmol,1.93mL约0.2mol/L的干燥DMF溶液),45℃下搅拌20h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得灰白色固体(0.0543g,35.43%)。m.p.314-316℃。
ESI-MS m/z:396.2(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):0.92(t,J=6.4Hz,6H),1.73-1.86(m,4H),7.01(d,J=8.4Hz,1H),7.23(d,J=8.4Hz,1H),7.41(s,1H),7.48(d,J=8.4Hz,1H),7.78(s,1H),7.92(d,J=8.4Hz,1H),8.20(s,1H),8.63(s,1H),10.36(s,1H),11.95(s,1H).
13C-NMR(100MHz,d
6-DMSO):161.6,159.6,152.1,135.6,133.3,133.2,128.5,127.0,124.9,124.3,121.3,118.9,117.6,117.4,114.5,103.8,92.0,30.4,8.1.
实施例8
2,2-二丙基-6-硝基-2H-苯并[e][1,3]嗪-4(3H)-酮
将5-硝基水杨酰胺(0.8g,4.395mmol)溶于甲苯(20mL)和4-庚酮(20mL)中,加入PPTS(1.1g,4.377mmol),N
2保护反应体系,90℃搅拌反应65h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=91/9-22/3),得白色固体(0.0558g,4.57%)。m.p.158-160℃。
ESI-MS m/z:278.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.95(t,J=7.3Hz,6H),1.44-1.54(m,4H),1.83-1.96(m,4H),7.03(d,J=9.0Hz,1H),8.28(s,1H),8.33(dd,J=9.0,2.7Hz,1H),8.81(d,J=2.6Hz,1H).
13C-NMR(100MHz,CDCl
3):161.3,160.9,142.2,129.7,124.2,117.9,116.8,93.4,40.7,16.7,14.0.
2,2-二丙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮
将6-硝基-2,2-二丙基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.1552g,0.558mmol)溶于无水乙醇(20mL)中,加入HCOONH4(0.282g,4.47mmol)、Pd/C(0.012g,0.1132mmol),室温搅拌4h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=17/3-2/1),得灰白色固体(0.0875g,63.23%)。m.p.119-121℃。
ESI-MS m/z:248.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):0.90(t,J=7.3Hz,6H),1.39-1.48(m,4H),1.73-1.85(m,4H),3.56(br s,2H),6.72(d,J=8.6Hz,2H),6.80(dd,J=8.6,2.6Hz,1H),7.23(d,J=2.6Hz,1H).
13C-NMR(100MHz,CDCl
3):162.9,148.8,140.6,122.0,117.6,117.5,113.1,90.8,40.1,16.8,14.1.
N-(2,2-二丙基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.063g,0.323mmol)溶于干燥的DMF(1.65mL)中,在搅拌的情况下分 别缓慢加入HATU(0.083g,0.218mmol,0.4mol/L的干燥DMF溶液)、三乙胺(0.717mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入2,2-二丙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.0537g,0.217mmol,1.1mL约0.2mol/L的干燥DMF溶液),45℃下搅拌9h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得灰白色固体(0.0285g,30.90%)。m.p.293-295℃。
ESI-MS m/z:424.0(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):0.87(t,J=7.3Hz,6H),1.39-1.43(m,4H),1.70-1.77(m,4H),6.98(d,J=8.8Hz,1H),7.23(dd,J=8.7,2.0Hz,1H),7.40(d,J=1.2Hz,1H),7.48(d,J=8.7Hz,1H),7.78(d,J=1.6Hz,1H),7.91(dd,J=8.8,2.6Hz,1H),8.19(d,J=2.6Hz,1H),8.61(s,1H),10.33(s,1H),11.92(s,1H).
13C-NMR(100MHz,d
6-DMSO):161.5,159.6,152.1,135.7,133.4,133.1,128.6,127.0,124.9,124.3,121.2,118.9,117.6,117.4,114.5,103.8,91.5,16.8,14.4.
实施例9
N-(2,2-二丙基-4-氧代-3,4-二氢-2H-苯并[e][1,3]嗪-6-基)-5-氯-1H-吡咯并[2,3-c]吡啶-2-甲酰胺
将5-氯-1H-吡咯并[2,3-c]吡啶-2-甲酸(0.10g,0.51mmol)和2,2-二丙基-6-氨基-2H-苯并[e][1,3]嗪-4(3H)-酮(0.15g,0.62mmol)溶于乙酸乙酯(5.0mL)中,加入吡啶(2.5mL),将反应体系置于冰浴中,向其中缓慢加入T
3P的乙酸乙酯溶液(1.0mL,50wt%),氮气保护下反应20h。反应结束后向其中加入0.5M的盐酸溶液(8.0mL),室温下搅拌2h。将所得悬浊液过滤,并用纯水冲洗3次。过滤,浓缩,乙醇/水重结晶得白色固体(40mg,18.3%)。
ESI-MS m/z:427.2(M+H)
+.
实施例10
6-硝基螺[苯并[e][1,3]嗪-2,1’-环戊烷]-4(3H)-酮(22i)
将5-硝基水杨酰胺(0.8g,4.395mmol)溶于甲苯(20mL)和环戊酮(20mL)中,加入PPTS(1.1g,4.377mmol),N
2保护反应体系,80℃搅拌反应49h,冷至室温,饱和NaHCO3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得白色固体(0.1702g,15.62%)。m.p.195-197℃。
ESI-MS m/z:249.0(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.90-2.02(m,6H),2.27-2.33(m,2H),7.08(d,J=9.2Hz,1H),8.35(dd,J=9.2,2.8Hz,1H),8.39(s,1H),8.84(d,J=2.8Hz,1H).
13C-NMR(100MHz,CDCl
3):161.9,161.0,142.5,129.6,124.4,118.3,117.6,99.2,38.7,22.7.
6-氨基螺[苯并[e][1,3]嗪-2,1’-环戊烷]-4(3H)-酮
将6-硝基螺[苯并[e][1,3]嗪-2,1’-环戊烷]-4(3H)-酮(0.1073g,0.4322mmol)溶于无水乙醇(25mL)中,加入HCOONH
4(0.234g,3.707mmol)、Pd/C(0.02g,0.188mmol),室温搅拌1h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=2/1),得褐色固体(0.055g,58.37%)。m.p.149-151℃。
ESI-MS m/z:218.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.77-1.88(m,6H),2.20-2.28(m,2H),3.62(br s,2H),6.77(d,J=8.4Hz,1H),6.81(dd,J=8.4,2.4Hz,1H),7.17(s,1H),7.24(d,J=2.4Hz,1H).
13C-NMR(100MHz,CDCl
3):163.8,149.1,141.0,121.8,118.2,117.9,113.1,97.1,38.1,22.7.
N-(4-氧代-3,4-二氢螺[苯并[e][1,3]嗪-2,1’-环戊烷]-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.067g,0.342mmol)溶于干燥的DMF(1.71mL)中,在搅拌的情况下分别缓慢加入HATU(0.087g,0.2288mmol,0.4mol/L的干燥DMF溶液)、三乙胺(0.717mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入6-氨基螺[苯并[e][1,3]嗪-2,1’-环戊烷]-4(3H)-酮(0.05g,0.229mmol,1.15mL约0.2mol/L的干燥DMF溶液),45℃下搅拌26h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重结晶得灰白色固体(0.0427g,47.21%)。
ESI-MS m/z:394.0(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):1.68-1.79(m,4H),1.80-1.88(m,2H),2.06-2.10(m,2H),7.01(d,J=8.8Hz,1H),7.23(d,J=8.6Hz,1H),7.41(s,1H),7.48(d,J=8.7Hz,1H),7.78(s,1H),7.93(dd,J=8.8,2.5Hz,1H),8.21(d,J=2.4Hz,1H),8.78(s,1H),10.35(s,1H),11.93(s,1H).
13C-NMR(100MHz,d
6-DMSO):162.1,159.7,152.3,135.7,133.5,133.3,128.6,126.8,124.9,124.3,121.3,119.1,118.3,117.7,114.5,103.8,98.0,37.9,22.9.
实施例11
6-硝基螺[苯并[e][1,3]嗪-2,1′-环己烷]-4(3H)-酮
将5-硝基水杨酰胺(0.8g,4.395mmol)溶于甲苯(15mL)和环己酮(15mL)中,加入PPTS(1.1g,4.377mmol),N
2保护反应体系,80℃搅拌反应48h,冷至室温,饱和NaHCO
3(15mL×4)和饱和NaCl(15mL×1)依次洗涤有机相,无水NaSO
4干燥过夜。过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=4/1-1/1),得白色固体(0.5209g,45.23%)。m.p.249-251℃。
ESI-MS m/z:262.8(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.45-1.82(m,8H),2.15(s,2H),7.11(d,J=8.8Hz,1H),7.80(s,1H),8.36(d,J=8.0Hz,1H),8.84(s,1H).
13C-NMR(100MHz,CDCl
3):160.9,160.4,142.4,129.7,124.3,118.2,117.6,89.9,36.4,24.3,21.8.
6-氨基螺[苯并[e][1,3]嗪-2,1′-环己烷]-4(3H)-酮
将6-硝基螺[苯并[e][1,3]嗪-2,1’-环己烷]-4(3H)-酮(0.52g,1.98mmol)溶于无水乙醇(50mL)中,加入HCOONH
4(1g,15.86mmol)、Pd/C(0.06g,0.566mmol),室温搅拌3h,过滤,浓缩,硅胶柱层析(石油醚/乙酸乙酯=2/1),得浅黄色固体(0.2404g,52.33%)。m.p.185-187℃。
ESI-MS m/z:232.9(M+H)
+.
1H-NMR(400MHz,CDCl
3):1.33-1.71(m,8H),2.11-2.08(m,2H),3.55(s,2H),6.76-6.83(m,2H),7.00(s,1H),7.23(d,J=2.3Hz,1H).
13C-NMR(100MHz,CDCl
3):162.9,148.4,140.9,121.9,118.1,117.8,113.1,87.5,35.9,24.7,22.0.
N-(4-氧代-3,4-二氢螺[苯并[e][1,3]嗪-2,1’-环己烷]-6-基)-5-氯-1H-吲哚-2-甲酰胺
将5-氯吲哚-2-羧酸(0.22g,1.12mmol)溶于干燥的DMF(5.6mL)中,在搅拌的情况下分别缓慢加入HATU(0.394g,1.036mmol,0.4mol/L的干燥DMF溶液)、三乙胺(3.16mmol,2mol/L的干燥DMF溶液),室温下搅拌10min后,加入6-氨基螺[苯并[e][1,3]嗪-2,1’-环己烷]-4(3H)-酮(0.24g,1.0345mmol,5.2mL约0.2mol/L的干燥DMF溶液),45℃下搅拌27h,冷至室温,饱和NaCl(15mL×3)洗涤有机相,乙酸乙酯萃取,无水NaSO
4干燥过夜。过滤,浓缩,乙醇/水重 结晶得灰白色固体(0.1244g,29.33%)。m.p.332-334℃。
ESI-MS m/z:409.4(M-H)
-.
1H-NMR(400MHz,d
6-DMSO):1.18-1.68(m,8H),2.00-2.03(m,2H),7.04(d,J=8.8Hz,1H),7.23(dd,J=8.8,1.6Hz,1H),7.41(s,1H),7.48(d,J=8.8Hz,1H),7.78(d,J=0.8Hz,1H),7.94(dd,J=8.8,2.4Hz,1H),8.20(d,J=2.4Hz,1H),8.67(s,1H),10.36(s,1H),11.95(s,1H).
13C-NMR(100MHz,d
6-DMSO):161.5,159.6,151.5,135.7,133.4,133.3,128.5,126.9,124.9,124.3,121.3,119.0,118.3,117.6,114.5,103.8,88.1,35.9,24.7.
实施例12 体外糖原磷酸化酶抑制活性试验
试剂的配制:1)显色液的配制:称量钼酸铵5g,溶解于500ml 1M HCl中,用搅拌器搅拌,至全部溶解后在加入孔雀绿190mg,继续搅拌至全部溶解,并用锡箔纸避光;2)缓冲液的配制:①精密称量Hepes 0.5958g,溶于5ml H
2O中,用10M NaOH调PH至7.2,配制成终浓度为0.5M的Hepes;②精密称量KCl 0.3728g,溶于5ml H
2O中,配制成终浓度为1M的KCl;③精密称量MgCl
30.0255g,溶于1ml H
2O中,配制成终浓度为125mM的MgCl
2;④精密称量EGTA 0.0476g,溶于5ml H
2O中,用10M NaOH调PH至7.0,配制成终浓度为25mM的EGTA;⑤精密称量G-1-P 0.0152g,溶于10ml H
2O中,配制成终浓度为5mM的G-1-P;⑥精密称量glycogen 10mg,溶于1ml H
2O中,配制成终浓度为10mg/ml的glycogen;3)阳性药caffeine溶液的配制:将caffeine溶于10ml H
2O配制0.5、5、50和500μM的溶液;4)配制GPa溶液:取1μl的GPa加入到100μl反应体系中,终浓度为250ng/100μl;5)待测试化合物溶液的配制:将待测试化合物溶于DMSO配制成浓度为10mM溶液,取适量化合物溶液加入到反应体系中至不同终浓度。
测定rabbit肌糖原磷酸化酶活性的量效曲线:通过读取不同浓度的GPa加入显色液后的在655nm下的OD值,来测定其量效曲线。由量效曲线可选择GPa的量为250ng。
实验步骤:1)设计PC(阳性对照)、Blank(空白对照)、阳性药(咖啡因);2)加反应buffer52μl;3)加测试化合物至终浓度;4)加酶1μl,终浓度为250ng/100μl;5)加显色液150μl;6)30摄氏度条件下反应20分钟;7)在波长655nm条件下比色;8)数据的读取及抑制率的计算:抑制率=[阳性对照-待测样品]/[阳性对照-空白对照]。
测试结果显示,大多数各实施例中的化合物IC
50<1μM,证明为有效,具体见下表1。该药理学数据显示,本发明通式(I)化合物具有糖原磷酸化酶的抑制作用,与已知化合物(CN103497181A实施例1化合物)活性类似。
表1式(I)化合物对rabbit肌糖原磷酸化酶的抑制活性
由以上试验可见,本发明的式(I)化合物具有抑制糖原磷酸化酶的活性,因此可以用于治疗与糖原代谢异常相关的各种疾病。
实施例13 药代动力学试验
取24只成年大鼠,禁食12小时后,随机分成2组,每组12只,依照前期研究经验按50mg/kg 灌胃给药,一组给予本发明实施例8化合物,一组给予现有技术化合物(CN103497181A实施例1化合物),给药后分别于0.25,0.5、1、2、3、4、6、8、10、12h经颈静脉穿刺采血。血浆样品0.2mL,加乙腈溶液0.4mL,旋涡震荡5min,10000r·min
-1离心10min,取上清液,10000r·min
-1离心10min,再取上清液,用HPLC法测定血浆中药物浓度。药动学参数如下表2:
表2
由以上实验可见,本发明的化合物与现有技术化合物(CN103497181A实施例1化合物)相比,具有更长的半衰期,更高的C
max,具有更优的生物利用度,从而提高了疗效。
实施例14 对高脂饲料诱导的2型糖尿病肥胖小鼠(DIO)的降糖实验
4周龄雄性C57 BL/6J小鼠适应性喂养5天后,随机选择10只小鼠为正常对照组,饲以低脂饲料,其余小鼠饲以高脂饲料。小鼠每5只一笼,自由进食和饮水,明暗周期为12h,室温22℃~26℃。小鼠连续喂养12周后,测定空腹和葡萄糖耐量评价胰岛素抵抗,显示造模成功。按照体重将高脂饲养组按照10只/组,随机均分以下各试验组:模型对照组,二甲双胍组(400mg/kg,灌胃)和实施例8化合物组(高、中、低剂量组分别为50、25、12.5mg/kg,灌胃,每天1次)。按实验分组连续给药4周,末次给药前禁食过夜。
模型对照组在给药第0、7、14、21、27天的血糖值显著高于正常对照组(
##p<0.01)。二甲双胍400mg/kg组在给药第7、21、27天血糖出现显著性差异,低于模型对照组(
**p<0.01);本发明实施例8化合物50mg/kg组在给药第7、14、21、27天血糖值均显著低于模型对照组(
*p<0.05,
**p<0.01),25mg/kg、12.5mg/kg组均在给药第21、27天血糖值显著低于模型对照组(
**p<0.01)。
表3本发明实施例8化合物对高脂饮食诱导的C57BL/6高血糖小鼠模型血糖的影响
#p<0.05、##p<0.01相对于正常对照组;
*p<0.05、
**p<0.01相对于模型对照组,(Mean±SEM,n=10)。
实施例15 对小鼠心肌缺血/再灌注(I/R)的保护作用
8周龄SPF级C57 BL/6J小鼠,体重20-25g,随机均分以下各试验组,10只/组:假手术组(Sham),I/R模型组(I.R Model)和实施例8化合物组高剂量组(HD 100mg/kg)、中剂量组(MD 50mg/kg)和低剂量组(LD 30mg/kg)。异氟烷麻醉小鼠,观察其无翻正反应后,使其仰卧位固定在手术操作板上。将小鼠胸前手术部位用75%酒精进行体表消毒,沿第3、4肋间剪开约1cm的切口,钝性分离胸大肌、胸小肌,持弯止血钳穿透肋间肌深入胸腔,借助其力量,迅速将心脏从肋间挤压出来。缝合针结扎其左前降支冠状动脉,造成小鼠心肌缺血,此刻可观察到左心室前壁变成苍白色。结扎后将心脏快速送回胸腔复位,将结扎活结线头暴露出体外,缝合针缝合皮肤切口。结扎的瞬间开始计时,缺血30min后,用手轻拉结扎线头,松开此结,恢复心脏供血,将小鼠放于37℃保温垫上至其恢复自动爬行能力。恢复心脏供血24小时后,I/R模型建立。实施例8化合物高、中、低剂量组经I/R造模后尾静脉注射给药,每天1次,连续给药7天。
暴露小鼠胸部,用医用棉签蘸取适量实验动物专用脱毛膏,均匀涂于小鼠胸颈部皮肤,用湿润的纸巾擦拭干净鼠毛,暴露心脏超声部位。选用小鼠专用超声探头(MS-400),麻醉小鼠,将其胸部朝上固定于手术操作板上,胸前均匀涂抹超声专用耦合剂,探头平放于小鼠胸腔中部,微调探头,大约逆时针旋转30°,通过B-mode模式观察清晰心脏的胸骨旁长轴切面,保存画面。再切换到M-mode模式,记录左心室直径最大处影像。通过分析软件处理数据,计算小鼠左心室的射血分数(EF),短轴缩短率(FS),舒张末容积(EDV)和收缩末容积(ESV)。结果发现,实施例8化合物在50-100mg/kg剂量处理下,显著改善I/R小鼠心脏的射血分数,缩短轴短率,恢复左心室的收缩和舒张末期容积,显著改善小鼠心脏功能。
注:LVEF:左室射血分数(Left Ventricular Ejection Fractions),是指:每搏输出量占心室舒张末期容积量的百分比。心室收缩时并不能将心室的血液全部射入动脉,正常成人静息状态下,心室舒张期的容积:左心室约为125mL,右心室约为137mL,博出量为60-80mL,即射血完毕时心室尚有一定量的余血,把博出量占心室舒张期容积的百分比称为射血分数,一般50%以上属于正常范围,人体安静时的射血分数约为55%~65%。射血分数与心肌的收缩能力有关,心肌收缩能力越强,则每搏输出量越多,射血分数也越大。正常情况下左室射血分数为≥50%;右心室射血分数为≥40%。若小于此值即为心功能不全。
LVFS:左室短轴缩短率(Left Ventricular Fractional shortening),是指:左心室舒张末期的内径减去左心室收缩末期内径,比上左心室舒张末期内径的百分比,这个值反映的是心脏的收缩和舒张功能。
LVEDV:左室舒张末期容积(Left VentricularEnd-diastolic volume),如字面意思,是指左室舒张末期心室内的容积,用于计算LVEF和LVFS。
LVESV:左室收缩末期容积(Left VentricularEnd-systolic volume),如字面意思,是指左室收缩末期心室内的容积,用于计算LVEF和LVFS。
以上,对本发明的实施方式进行了说明。但是,本发明不限定于上述实施方式。凡在本发明的精神和原则之内,所做的任何修改、等同替换、改进等,均应包含在本发明的保护范围之内。
Claims (10)
- 如下式(I)化合物或其药学上可接受的盐其中:X 1、X 2、X 3和X 4全为C或者X 1、X 2、X 3和X 4之一为N而其他的必须为C;R 1和R 1’各自独立为H、卤素、羟基、氰基、C 1-4烷基、C 1-4烷氧基、氟代甲基、二氟甲基、三氟甲基、乙烯基、乙炔基;R 2和R 2’各自独立为H、卤素、羟基、氰基、C 1-4烷基、C 1-4烷氧基、氟代甲基、二氟甲基、三氟甲基、乙烯基、乙炔基;R 3为H、1-20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基、非取代或X取代的芳基、非取代或X取代的杂芳基;R 4和R 5各自独立为H、1-20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基,R 4和R 5任选可以成环;Y为CHR 6、NH、O、S;R 6为H、1~20个碳的非取代的或X取代的直链或支链烷基、2-20个碳的非取代的或X取代的直链或支链烯烃基、2-20个碳的非取代的或X取代的直链或支链炔烃基、苯基、苄基、萘基、腈基;X为F、Cl、Br、I、CN、NO 2、NH 2、CF 3、SH、OH、OCH 3、OC 2H 5、COOH、1-10个碳的直链或支链烷基、2-10个碳的直链或支链烯烃基、2-10个碳的直链或支链炔烃基、芳基、杂芳基。
- 如权利要求1或2所述的化合物,其特征在于,式(I)和式(II)化合物中:X 1、X 2、X 3和X 4全为C或者X 2、X 3之一为N而其他的必须为C;R 1和R 1’各自独立为H、卤素、氰基、C 1-4烷氧基;R 2和R 2’各自独立为H;R 3为H、1-20个碳的非取代的或X取代的直链或支链烷基、非取代或X取代的C 6-14芳基、非取代或X取代的C 5-10杂芳基;R 4和R 5各自独立为H、1-20个碳的非取代的或X取代的直链或支链烷基,R 4和R 5任选可以成环;Y为CH 2、NH、O;X为F、Cl、Br、I、CN、NO 2、NH 2、CF 3、SH、OH、OCH 3、OC 2H 5、COOH、1-10个碳的直链或支链烷基、2-10个碳的直链或支链烯烃基、2-10个碳的直链或支链炔烃基、C 6-14芳基、C 5-10杂芳基。优选地:X 1、X 2、X 3和X 4全为C或者X 2、X 3之一为N而其他的必须为C;R 1和R 1’各自独立为H、F、Cl、Br、氰基、甲氧基;R 2和R 2’各自独立为H;R 3为H、1-6个碳的非取代的或X取代的直链或支链烷基;R 4和R 5各自独立为H、1-6个碳的非取代的或X取代的直链或支链烷基,例如甲基、乙基、正丙基、异丙基、正丁基、仲丁基、异丁基、叔丁基、正戊基、异戊基、新戊基等,R 4和R 5任选可以成环,例如五元环(例如环戊基)、六元环(例如环己基)、七元环(例如环庚基)等;Y为O;X为F、Cl、Br、I、CN、NO 2、NH 2、CF 3、SH、OH、OCH 3、OC 2H 5、COOH、1-6个碳的直链或支链烷基。
- 如权利要求1-4中任一项所述的化合物的制备方法,其特征在于,包括如下步骤:a)将 溶于氨水中或者溶于有机溶剂中并加入氨水,优选在惰性气体进一步优选氮气保护下,反应1-72小时,优选24-48小时,温度为0℃至回流,得 其中,R 3’为有机基团,优选甲基、乙基、丙基、异丙基、正丁基、异丁基、叔丁基、苯甲基等;优选地,所述有机溶剂选自二氧六环、四氢呋喃、二氯甲烷、1,2-二氯乙烷、氯仿、甲苯、正己烷、环己烷、叔丁基甲基醚、吡啶和其中两种或多种的混合物,进一步优选二氧六环、四氢呋喃或其混合物;b)将 溶于有机溶剂中,加入 和催化剂PPTS,优选在惰性气体进一步优选氮气保护下,反应1-72小时,温度为0℃至回流,得 优选地,所述有机溶剂选自苯、甲苯、二甲苯、二氧六环、DMF、DMSO、乙腈和其中两种或多种的混合物,进一步优选二氧六环、甲苯、二甲苯和其中两种或多种的混合物;c)将 溶于有机溶剂中,加入氢源,采用金属催化剂催化还原苯环上的硝基,温度为0℃至回流,得 优选地,所述金属催化剂选自钯碳、雷尼镍、铁粉、锌粉,氯化亚锡;优选地,所述氢源选自氢气、水合肼、甲酸胺、甲酸、氯化铵、环己烯;优选地,所述有机溶剂选自甲醇、乙醇、正丁醇、叔丁醇、四氢呋喃、二氯甲烷、1,2-二氯乙烷、氯仿、甲苯、正己烷、环己烷、叔丁基甲基醚和其中两种或多种的混合物,进一步优选甲醇、乙醇或其混合物;d)将取代的吲哚羧酸或吡咯并吡啶-2-羧酸 与 溶于有机溶剂中,加入缩合试剂与有机胺或无机碱,反应1-72小时,温度为0℃至45℃,即得;优选地,所述有机溶剂为惰性溶剂,进一步优选非质子性溶剂,进一步优选有机溶剂选自乙腈、氯仿、二氯甲烷、1,2-二氯乙烷、N,N-二甲基甲酰胺、甲苯、正己烷、环己烷、四氢呋喃、叔丁基甲基醚和其中两种或多种的混合物,进一步优选有机溶剂选自二氯甲烷、1,2-二氯乙烷或、N,N-二甲基甲酰胺和其中两种或多种的混合物;优选地,所述缩合试剂为酰胺化缩合试剂,进一步优选1-乙基-3-(3-二甲胺丙基)碳二亚胺盐酸盐(EDCI)、N,N′-二环己基碳二亚胺(DCC)、O-苯并三氮唑-N,N,N′,N′-四甲基脲四氟硼酸(TBTU)、2-(7-偶氮苯并三氮唑)-N,N,N′,N′-四甲基脲六氟磷酸酯(HATU)、1-丙基磷酸三环酸酐(T 3P);优选地,所述无机碱选自碳酸钠、碳酸氢钠、碳酸钾、碳酸氢钾和其中两种或 多种的混合物;优选地,所述有机胺为N,N-二异丙基乙胺、三乙胺或其混合物。优选地,进一步包括如下步骤:
- 一种药物组合物,其特征在于,含有如权利要求1-4任一项所述的化合物或其药学上可接受的盐,以及药学上可接受的辅料。
- 一种用于预防和/或治疗与糖原代谢异常相关的疾病的方法,包括给予有需要的个体有效量的如权利要求1-4任一项所述的化合物或其药学上可接受的盐或者如权利要求6所述的药物组合物。
- 如权利要求1-4任一项所述的化合物或其药学上可接受的盐或者如权利要求6所述的药物组合物在制备用于治疗和/或预防与糖原代谢异常相关的疾病的药物中的用途。
- 如权利要求7所述的方法或者如权利要求8所述的用途,其特征在于,所述与糖原代谢异常相关的疾病包括糖尿病(特别是2型糖尿病)或其并发症(例如糖尿病肾病、糖尿病足、糖尿病神经病变、糖尿病并发的心脑血管疾病等)、高脂血症、肥胖、缺血性心脑血管疾病(特别是心肌梗死、心绞痛、心肌缺血、心肌缺血再灌注、心律失常、冠心病、脑缺血、中风、脑梗死或缺血性神经退行性疾病等)、高胰岛素血症、胰岛素抵抗、禁食高血糖症、高血压或其并发症、动脉粥样硬化、代谢综合征或肿瘤。
- 如权利要求1-4任一项所述的化合物或其药学上可接受的盐或者如权利要求6所述的药物组合物在制备糖原磷酸化酶抑制剂中的用途。
Priority Applications (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/074002 WO2022160138A1 (zh) | 2021-01-27 | 2021-01-27 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
Applications Claiming Priority (1)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
PCT/CN2021/074002 WO2022160138A1 (zh) | 2021-01-27 | 2021-01-27 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2022160138A1 true WO2022160138A1 (zh) | 2022-08-04 |
Family
ID=82654000
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/CN2021/074002 WO2022160138A1 (zh) | 2021-01-27 | 2021-01-27 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
Country Status (1)
Country | Link |
---|---|
WO (1) | WO2022160138A1 (zh) |
Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452526A1 (en) * | 2001-10-29 | 2004-09-01 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
WO2006059164A2 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
CN1826340A (zh) * | 2003-05-21 | 2006-08-30 | 普罗西迪恩有限公司 | 作为糖原磷酸化酶抑制剂的吡咯并吡啶-2-甲酸酰胺 |
CN101622231A (zh) * | 2007-02-28 | 2010-01-06 | 艾德维纳斯医疗私人有限公司 | 作为葡糖激酶激活剂的2,2,2-三取代的乙酰胺衍生物、它们的制造方法和药学应用 |
CN103497181A (zh) * | 2013-09-30 | 2014-01-08 | 承德医学院 | 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途 |
WO2014097188A1 (en) * | 2012-12-21 | 2014-06-26 | C4T S.C. A.R.L. | Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them |
CN112442022A (zh) * | 2019-09-02 | 2021-03-05 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
-
2021
- 2021-01-27 WO PCT/CN2021/074002 patent/WO2022160138A1/zh active Application Filing
Patent Citations (7)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP1452526A1 (en) * | 2001-10-29 | 2004-09-01 | Japan Tobacco Inc. | Indole compound and medicinal use thereof |
CN1826340A (zh) * | 2003-05-21 | 2006-08-30 | 普罗西迪恩有限公司 | 作为糖原磷酸化酶抑制剂的吡咯并吡啶-2-甲酸酰胺 |
WO2006059164A2 (en) * | 2004-12-02 | 2006-06-08 | Prosidion Limited | Pyrrolopyridine-2-carboxylic acid amides |
CN101622231A (zh) * | 2007-02-28 | 2010-01-06 | 艾德维纳斯医疗私人有限公司 | 作为葡糖激酶激活剂的2,2,2-三取代的乙酰胺衍生物、它们的制造方法和药学应用 |
WO2014097188A1 (en) * | 2012-12-21 | 2014-06-26 | C4T S.C. A.R.L. | Compounds of 2,3-dihydro-4h-1,3-benzoxazine-4-one, method for preparing them and pharmaceutical form comprising them |
CN103497181A (zh) * | 2013-09-30 | 2014-01-08 | 承德医学院 | 作为糖原磷酸化酶抑制剂的苯并氮杂卓酮类化合物、其制备方法及医药用途 |
CN112442022A (zh) * | 2019-09-02 | 2021-03-05 | 承德医学院 | 苯并嗪-4-酮类化合物、其制备方法及医药用途 |
Non-Patent Citations (1)
Title |
---|
DATABASE REGISTRY 7 February 2012 (2012-02-07), ANONYMOUS : "1H-Indole-2-carboxamide, 6-ethoxy-N-(1,2,3,4-tetrahydro-1-oxo-7- isoquinolinyl)-(CA INDEX NAME) ", XP055954994, retrieved from STN Database accession no. 1355639-22-3 * |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
JP6238908B2 (ja) | リシン構造を有するlsd1選択的阻害薬 | |
EP1404653B1 (en) | Triamide-substituted indoles, benzofuranes and benzothiophenes as inhibitors of microsomal triglyceride transfer protein (mtp) and/or apolipoprotein b (apo b) secretion | |
JP4196678B2 (ja) | 複素環化合物 | |
EP2878594B1 (en) | Difluoromethylene compound | |
KR20210143803A (ko) | Tead 전사인자의 신규한 소분자 저해제 | |
EA012204B1 (ru) | Три(цикло)замещённые амидные соединения | |
KR20030015390A (ko) | 지질 풍부 플라크 퇴축제 | |
JP2007509959A (ja) | トリアゾール化合物およびそれに関連する使用法 | |
WO2018157843A1 (zh) | 2-(取代苯杂基)芳香甲酸类fto抑制剂,其制备方法及其应用 | |
TW200942239A (en) | Phenylacetamide derivatives | |
JP2013537240A (ja) | 糖尿病および脂質異常症の処置のための方法および組成物 | |
TW201536722A (zh) | 新穎化合物 | |
JP2020520949A (ja) | 組成物、並びにミトコンドリア脱共役剤を調製及び使用する方法 | |
CA2931836C (en) | P-substituted asymmetric ureas and medical uses thereof | |
TW479058B (en) | 2,7-substituted octahydro-pyrrolo[1,2-a]pyrazine derivatives | |
UA120389C2 (uk) | Нові сполуки піридинію | |
WO2022143574A1 (zh) | 2-吡啶酮类衍生物及其制备方法和在医药上的应用 | |
WO2019096089A1 (zh) | 吲哚嗪衍生物及其在医药上的应用 | |
WO2022160138A1 (zh) | 苯并嗪-4-酮类化合物、其制备方法及医药用途 | |
JP5372514B2 (ja) | 新規なインドリジン誘導体、この調製方法およびこれを含む治療組成物 | |
WO2002006249A1 (fr) | Procede de fabrication d'un derive de 1,2,3 triasol substitue en position 1 | |
CN112442022B (zh) | 苯并嗪-4-酮类化合物、其制备方法及医药用途 | |
WO2017016523A1 (zh) | 靶向idh2突变的抗肿瘤化合物及其使用方法 | |
Robertson et al. | Imidazole-pyridine bioisosterism: comparison of the inotropic activities of pyridine-and imidazole-substituted 6-phenyldihydropyridazinone cardiotonics | |
WO2018205928A1 (zh) | 吲哚嗪衍生物及其在医药上的应用 |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 21921758 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 21921758 Country of ref document: EP Kind code of ref document: A1 |